    
 
 
A randomized , multicenter , parallel- group, Phase III study to compare the 
efficacy of a rfolitixorin versus leucovorin in combination with 5 -fluorouracil, 
oxaliplatin, and bevacizumab in patients with advanced colorectal cancer  
 
Protocol Number: IS0- CC-007 
Drug Product: a rfolitixorin  
 
Global Coordinating Investigator : Josep Tabernero,  MD, PhD , Prof  
US Coordinating Investigator: Heinz -Josef Lenz, MD, Prof  
IND/IDE  number:  127894  
EudraCT number:  2017- 004154- 41 
 
Sponsor : Isofol Medical AB  (publ) , Gothenburg, Sweden 
 
Version Number: 9 .0 USA  
22 April 2022  
 
Summary of Changes  from Previous Version:  
Version no.  Date  Type of change (Amendment or Admin)  
1.0 21 September  2018 Initial version  
2.0 13 November 2018  Administrative change  
3.0 USA  25 January 2019  Local amendment  
4.0 USA  29 August 2019 Global amendment  
5.0 USA  07 October 2019  Administrative change  
6.0 USA  20 February 2020  Global amendment  
7.0 USA  20 August  2021 Global amendment  

NIH-FDA Phase 2 and 3 IND/IDE Clinical Trial Protocol Template    
 ii 8.0 USA  22 February 2022  Global Amendment. Never submitted, changes included in 
v 9.0 
9.0 USA  22 February 2022  Global Amendment  
For more detailed information regarding the changes, see section 10.3 in this study protocol.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 ii   Table of Contents  
STATEMENT OF COMPLIANCE ...................................................................................................... 1  
CONFIDENTIALITY STATEMENT  .................................................................................................... 1  
SIGNATURE PAGE Protocol approval  ............................................................................................. 2  
SIGNATURE PAGE Study Coordinators  .......................................................................................... 3  
SIGNATURE PAGE Investigator  ....................................................................................................... 4  
1 PROTOCOL SUMMARY  ......................................................................................................... 5  
1.1 Synopsis  ........................................................................................................................... 5  
1.2 Schema  ........................................................................................................................... 14 
1.3 Schedule of Ac tivities (SoA)  ........................................................................................ 15 
2 INTRODUCTION  .................................................................................................................... 17 
2.1 Study Rationale  ............................................................................................................. 17 
2.1.1  Advanced Colorectal Cancer  ..................................................................... 17 
2.1.2  Current standard of care  ............................................................................ 17 
2.1.3  Mechanism of action of Arfolitixorin .......................................................... 18 
2.2 Background  .................................................................................................................... 19 
2.2.1  Non-clinical Background ............................................................................ 19 
2.2.2  Clinical Background .................................................................................... 19 
2.3 Risk/Benefit Assessment  ............................................................................................. 21 
2.3.1  Known Potential Risks  ................................................................................ 21 
2.3.2  Known Potential Benefits  ........................................................................... 21 
2.3.3  Assessment of Potential Risks and Benefits  .......................................... 21 
3 OBJECTIVES AND ENDPOINTS  ........................................................................................ 24 
4 STUDY DESIGN  ..................................................................................................................... 25 
4.1 Overall Design  ............................................................................................................... 25 
4.2 Scientific Rationale for Study Design  ......................................................................... 26 
4.3 Justification for Dose  .................................................................................................... 27 
4.4 End of Study Definition ................................................................................................. 29 
5 ST
UDY POPULATION  ........................................................................................................... 29 
5.1 Inclusion Criteria ............................................................................................................ 29 
5.2 Exclusion Criteria  .......................................................................................................... 30 
5.3 Lifestyle Considerations  ............................................................................................... 31 
5.4 Screen Failures  ............................................................................................................. 31 
5.5 Strategies for Recruitment and Retention ................................................................. 31 
6 STUDY INTERVENTION ....................................................................................................... 32 
6.1 Study Intervention(s) Administration .......................................................................... 32 
6.1.1  Study Intervention Description .................................................................. 32 
6.1.2  Dosing and Administration ......................................................................... 32 
6.2 Preparation/Handling/Storage/Accountability  ........................................................... 33 
6.2.1  Acquisition and accountability  ................................................................... 33 
6.2.2  Formulation, Appearance, Packaging, and Labelling ............................ 34 
6.2.3  Product Storage and Stability  .................................................................... 35 
6.2.4  Preparation  ................................................................................................... 35 
6.3 Other Medications  ......................................................................................................... 36 
6.3.1  5-FU 36 
6.3.2  Oxaliplatin  ..................................................................................................... 36 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 iii 6.3.3  Bevacizumab  ............................................................................................... 37 
6.3.4  Dose adjustements  ..................................................................................... 37 
6.4 Measures to Minimize Bias: Randomization and Blinding  ...................................... 38 
6.4.1  Randomization ............................................................................................. 38 
6.4.2  Blinding  38 
6.5 Study Intervention Compliance  ................................................................................... 38 
6.6 Concomitant Therapy  ................................................................................................... 39 
6.6.1 Prohibited Therapies ................................................................................... 39 
6.6.2  Authorized Medication  ................................................................................ 39 
6.6.3  Rescue Medicine  ......................................................................................... 39 
7 IMP DISCONTINUATION AND PATIENT DISCONTINUATION  .................................... 39 
7.1 Discontinuation of Study Intervention  ........................................................................ 39 
7.2 Participant Discontinuation/Withdrawal from the Study  .......................................... 40 
7.3 Lost to Follow -Up .......................................................................................................... 40 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................................................ 41 
8.1 Efficacy Assessments  .................................................................................................. 41 
8.1.1  CT scan / MRI  .............................................................................................. 41 
8.1.2  Pharmacokinetics  ........................................................................................ 43 
8.1.3  ECOG performance status  ........................................................................ 45 
8.1.4  EQ-5D Quality of life  ................................................................................... 45 
8.1.5  Survival Status  ............................................................................................. 45 
8.2 Safety and Other Assessments  .................................................................................. 46 
8.2.1  Laboratory safety assessments  ................................................................ 46 
8.2.2  Vital signs, ECG and physical findings related to safety  ....................... 46 
8.2.3  PRO CTCAE  ................................................................................................ 47 
8.2.4  Pharmacogenetics  ...................................................................................... 47 
8.2.5  RESECTION/REMOVAL OF TUMOR LESION(S)  ................................ 48 
8.3 Study Schedule  ............................................................................................................. 48 
8.
3.1 Screening and Enrollment  ......................................................................... 48 
8.3.2  Baseline (Cycle 1)  ....................................................................................... 49 
8.3.3  Treatment Period ......................................................................................... 49 
8.3.4  End of treatment visit (EOT)  ...................................................................... 50 
8.3.5  Post-Treatment visits  .................................................................................. 50 
8.4 Adverse Events and Serious Adverse Events  .......................................................... 51 
8.4.1  Definition of Adverse Events (AE)  ............................................................ 51 
8.4.2  Definition of Serious Adverse Events (SAE)  ........................................... 51 
8.4.3  Classification of an Adverse Event  ........................................................... 52 
8.4.4  Time Period and Frequency for Event Assessment and Follow- Up ... 54 
8.4.5  Adverse Event Reporting  ........................................................................... 54 
8.4.6  Adverse Event of Special Interest  ............................................................ 54 
8.4.7  Serious Adverse Event Reporting  ............................................................ 54 
8.4.8  Reporting Events to Participants  .............................................................. 55 
8.4.9  Reporting of Pregnancy  ............................................................................. 55 
9 STATISTICAL CONSIDERATIONS ..................................................................................... 56 
9.1 Statistical Hypotheses  .................................................................................................. 56 
9.2 Sample Size Determination ......................................................................................... 56 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 iv 9.2.1  Primary efficacy endpoint: ORR  ............................................................... 56 
9.2.2  Secondary efficacy endpoint: PFS  ........................................................... 57 
9.2.3  Hierarchical testing approach .................................................................... 57 
9.2.4  Overall survival  ............................................................................................ 58 
9.2.5  Accrual rate  .................................................................................................. 58 
9.3 Populations for Analyses  ............................................................................................. 58 
9.4 Statistical Analyses  ....................................................................................................... 59 
9.4.1 General Approach  ....................................................................................... 59 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  .......................................... 59 
9.4.3  Analysis of the Secondary Endpoint(s)  .................................................... 59 
9.4.4  Safety Analyses  ........................................................................................... 60 
9.4.5  Baseline Descriptive Statistics  .................................................................. 60 
9.4.6  Planned Interim and final Analyses  .......................................................... 60 
9.4.7  Sub-Group Analyses ................................................................................... 63 
9.4.8  Tabulation of Individual participant Data  ................................................. 63 
9.4.9  Exploratory Analyses  .................................................................................. 63 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ........ 64 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ...................................... 64 
10.1.1  Informed Consent Process ........................................................................ 64 
10.1.2  Study Discontinuation and Closure  .......................................................... 65 
10.1.3  Confidentiality and Privacy  ........................................................................ 65 
10.1.4  Future Use of Stored Specimens and SAMPLES  .................................. 65 
10.1.5  Key Roles and Study Governance  ........................................................... 65 
10.1.6  Safety Oversight  .......................................................................................... 66 
10.1.7  Clinical Monitoring  ....................................................................................... 66 
10.1.8  Quality Assurance  ....................................................................................... 67 
10.1.9  Data Handling and Record Keeping  ......................................................... 68 
10.1.10  Protocol Deviations  ..................................................................................... 69 
10.
1.11  Publication and Data Sharing Policy  ........................................................ 70 
10.1.12  Insurance  ...................................................................................................... 70 
10.1.13  Conflict of Interest Policy  ........................................................................... 70 
10.2  Abbreviations  ................................................................................................................. 72 
10.3  Protocol Amendment History  ...................................................................................... 74 
11 REFERENCES  ........................................................................................................................ 79 
 
 
     
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 v  
 
 
 Tables 
Table 1: Schedule of Activities (SOA)  ............................................................................................. 15 
Table 2: Components of arfolitixorin ................................................................................................ 34 
Table 3: Laboratory tests  .................................................................................................................. 46 
Table 4: Hazard ratio for significance in function of the number of PFS events  ...................... 57 
Table 5: Guidelines for sample size increase at interim analysis  ............................................... 62 
 
 
Appendices  
Appendix 1: ECOG performance status scale  
Appendix 2:  NCI PRO  CTCAE  
Appendix 3: EuroQol EQ-5D
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 1 STATEMENT OF COMPLIANCE  
 
The trial will be conducted in accordance with International Conference on Harmonization Good Clinical Practice (ICH GCP), the provisions of the Helsinki Declaration, and the relevant legislation in 
force. For US based clinical sites, the study will be conducted under an IND. For sites based outside of 
the US (Non -IND sites), the study will be conducted according to GCP and other applicable local laws 
and regulation. The Principal Investigator will assure that no deviation from, or changes to the protocol 
will take place without written approval by an adequately constituted Institutional Review Board/Ethics Committee and Regulatory Authorities, except where necessary to eliminate an imme diate hazard(s) to the study patients.  All personnel involved in the conduct of this study have 
completed ICH GCP Training and have appropriate knowledge about other applicable regulation, including Human Subject Protection and GDPR.  
 
The protocol, informe d consent form(s), recruitment materials, and all participant materials will be 
submitted to the Ethics Committee and/or Regulatory Authorities for review and approval. Approval of both the protocol and the consent form must be obtained befo re any participant is enrolled.  Any 
amendment to the protocol will require review and approval by the Ethics Committee and/or Regulatory Authorities  before the changes are implemented to the study.  All changes to the consent 
form will be Ethics Committee and/or Regulatory Authorities  approved; a determination will be made 
regarding whether  a new consent needs to be obtained from participants who provided consent, using 
a previously  approved consent form . 
 
CONFIDEN TIALITY STATEMENT 
 This Clinical Study Protocol (CSP) contains information that is confidential and proprietary to Isofol Medical AB (publ)  (Sponsor ). This information is being provided to you for the purpose of conducting 
a clinical study sponsored by Isofol . You may disclose the contents of this CSP to study personnel under 
your supervision who need to know the contents for this purpose, as well as to your Independent Ethics Committee/Institutional Review Board (IEC/IRB) . The contents of this CSP may not be disclosed 
to any other person or entity without  the prior written permission of Isofol and may not be used for 
any other purpose than the conduct of this study . The foregoing shall not apply to disclosure required 
by governmental regulations or laws; however, you will give prompt notice to Isofol of an y such 
disclosure.  
 Any supplemental information that may be added to this document is also confidential and proprietary to Isofol and must be kept in confidence in the same manner as the contents of this CSP.  
 Any person who receives this CSP without due authorization  from Isofol is requested to return it to 
Isofol or to promptly destroy it.  
   
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 2 SIGNATURE PAGE PROTOCOL APPROVAL  
 
The signature s below constitute the approval of this protocol and the appendices , and provides the 
necessary assurances that this  protocol has been designed and the  study will be conducted according 
to all stipulations of  GCP and according to all applicable legal and regulatory requirements.  
  Sponsor â€™s Representative:  
    Roger Tell , MD, PhD  Date: 
Chief Medical Officer   
Isofol Medical AB (publ)  
 --------------------------------------------------------------------------------------------------------------------------------------  
     
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 3  
SIGNATURE PAGE STUDY COORDINATORS  
 
I have read and understood this study protocol,  and I agree to conduct the study according to the 
study protocol , GCP and applicable local regulation . 
 
Biostati stician:  
    Koenraad  D`Hollander, MSc  Date :  
IDDI  
Louvain -la-Neuve , Belgium  
 --------------------------------------------------------------------------------------------------------------------------------------  
 Global Coordinating Investigator : 
    Josep Tabernero, MD, PhD, MSc  Date :  
Vall Dâ€™Hebron Institute of Oncology  
Barcelon a, Spain  
 
 
--------------------------------------------------------------------------------------------------------------------------------------  
  US Coordinating Investigator:     Heinz- Josef Lenz, MD, FACP  Date : 
University of Southern California  
Norris Comprehensive Cancer Center  
Los Angeles, USA  
 
  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 4  
SIGNATURE PAGE INVESTIGATOR  
 
I have read and understood this study protocol,  and I agree to conduct the study according to the 
study protocol , GCP and applicable local regulation . 
 
Site investigator signature  
 Principal Investigator (Sign) : 
  Name  (Block letters) : Date : 
 
Site:  
  --------------------------------------------------------------------------------------------------------------------------------------  
  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 5 1 PROTOCOL SUMMARY  
1.1 SYNOPSIS   
   
Study title  A randomized , multi -center , parallel- group, Phase III study to compare the efficacy 
of arfolitixorin  versus  leucovorin in combination with 5 -fluorouracil, oxaliplatin, 
and bevacizumab in patients with advanced  colorectal cancer.  
 
Global 
Coordinating Investigator  Josep Tabernero, MD, PhD, MSc  
Vall Dâ€™Hebron Institute of Oncology  
Barcelona, Spain   
US Coordinating 
Investigator  Heinz -Josef Lenz, MD, PhD 
Division of Medical Oncology, University of Southern California  
Norris Comprehensive Cancer Center  
Los Angeles, CA , USA  
 
Study Duration  Recruitment period:  Q4 2018 â€“ Q2 2021 
Study period:   Q4 2018 â€“ Q1 2023  
Participant duration All patients will be treated until progressive disease (PD) , or toxicity,  and followed 
for survival until end of study.  
 
Short Summary  This is a multicenter , randomized , parallel- group, Phase III study in a t least  440 
patients with advanced colorectal cancer to compare the efficacy of treatment 
with arfolitixorin  versus L eucovorin in combination with 5 -fluorouracil, oxaliplatin, 
and bevacizumab according to modified FOLFOX -6 until PD according to RECIST 
1.1 criteria.   
 
Primary Endpoint  Overall  Response Rate (ORR) 
Background 
5-fluorouracil (5 -FU) in combination with the folate L eucovorin (LV) has been the 
cornerstone in the treatment of colorectal cancer (CRC) for decades.  All folates 
currently approved for use in the clinical setting need to be metabolically activated 
to [6R] 5,10 -methylenetetrahydrofolic acid ([6R] -MTHF), whic h is the active 
thymidylate synthase co -substrate that potentiates the effect of 5 -FU.  
Arfolitixorin  does not need multi step metabolic activation like currently available 
folates. It is therefore hypothesized that the administration of arfolitixorin will 
result in high er, and more consistent, intracellular concentrations of the active 
thymidylate synthase co -substrate [6R] -MTHF in all patients compared to LV 
administration.   
Indication First line advanced  CRC patients eligible for treatment with 5-FU, o xaliplatin, and  
bevacizumab.  
 
  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 6 Objectives and 
endpoints  
 Objective:  Endpoint/Outcome Measure: 
Primary  
Overall response rate (ORR)  Best ORR, defined as the best response 
recorded from the start of the study 
treatment until the end of treatment. All 
responses will be confirmed 8 weeks after onset of response. All assessments including confirmation of response will be performed by BICR.     
Key Secondary  
Progression -free survival (PFS)  PFS, defined as the time from 
randomization to first occurrence of tumor progression assessed by BICR (RECIST 1.1)  based on CT -scans/MRIs 
conducted every 8 weeks after start of treatment , or death from any cause .  
Duration of Response (DOR)  The duration of overall response (DOR) is measured from the first time point at 
which criteria are met for complete 
response (CR) or partial response (PR)  
through the last time point when overall response has been objectively documented.   
  
Other Secondary (efficacy)  
Overall survival (OS)  OS, defined as time from randomization to death from any cause  
Quality of Life  Quality of Life  assessed using the EQ-5D 
patient reported outcome questionnaire  
(PRO) . 
Other Secondary (safety)  
Safety and tolerability  Number and severity of adverse events (AEs), including clinically significant abnormal laboratory findings, regardless of causal relationship to arfolitixorin  or 
LV. Specific AEs will be followed using 
PRO ( NCI PRO -CTCAE ). 
Patients undergoing curative metastasis resection.  Defined as the number of patients 
qualifying for curative metastasis 
resection after treatment with study drug.  
Exploratory  
Daily living abilities  Daily living abilities as assessed by the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 7  
 
  To determine the pharmacokinetic 
(PK) characteristics of arfolitixorin and 
LV in patients with advanced CRC The plasma concentration  of methylene 
tetrahydrofolate ([6R] -MTHF), methyl -
tetrahydrofolate (methyl -THF),  and 
tetrahydrofolate (THF)  will be 
determined in a limited number of 
patients in both treatment arms.  
To investigate folate metabolism - and 
transportation -related gene 
expression levels in patients with advanced CRC Gene expression levels of folate metabolism - and transportation -related 
genes, analyzed by sub -group low/high 
gene expression levels . 
 Recurrence Free Survival (RFS) for patients undergoing metastatic resection.  Defined as the time between the first surgery with complete removal of the metastasis and recurrence of the disease or death from any cause.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 8  
 
 
1  Female patients must be post -menopausal for more than one year or must provide a negative urine 
pregnancy test and use an efficient method of contraception (i.e., a method with less than 1% failure rate [e.g., 
sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner]) during the study and for 1 month (or more if requested by non- IMP labels)  after the end of the study (last dose 
of IMP).
 
2  Unless the partner of a male patient is post -menopausal or using an efficient method of contraception 
as described above,  male patients must ag ree to use condoms during the study treatment and for 1 month 
after the end of the study treatment .  
Main Selection 
Criteria  
  
Inclusion criteria  
For randomization in the study, patients must fulfill all the following criteria:  
1. Colorectal adenocarcinoma verified by biopsy.  
2. Availability of biopsy material, from the primary tumor or metastasis, allowing 
for analysis of tumor gene e xpression.  
3. Non -resectable metastatic CRC planned for first line therapy with 5 -FU, 
Leucovorin,  oxaliplatin , and bevacizumab .   
4. Evaluable disease with at least one measurable lesion of metastatic disease  
(â‰¥10 mm in longest diameter on axial image on CT -scan  or alternatively MRI 
with <5 mm reconstruction interval) or lymph node (â‰¥ 15 mm in shortest axis 
when assessed by CT) obtained within 28 days of randomization.  
5. Life expectancy of more than 4 months.  
6. ECOG performance status 0 or 1.  
7. Hemoglobin (Hb) > 80 g/L, Absolute neutrophil count (ANC) > 1.5x109/L. 
Thrombocytes > 100x109/L.  
8. Creatinine clearance  > 50 mL/min, Total bilirubin  < 1.5 x ULN, AST and ALT  < 3 
x ULN (and <  5 x ULN in case of liver metastases).  
9. Male or female â‰¥18 years of age. 
10. Female patients of childbearing potential must have a negative urine 
pregnancy test and use adequate contraceptive measures1.  Male patients 
must use adequate contraceptive measures2. 
11. Voluntarily signed  informed consent  before performance of  any study related 
procedure not part of normal medical care, with the understanding that 
consent may be withdrawn by the patient  at any time without prejudice to 
future medical care.  
 
Exclusion Criteria  
Patients meeting one or more of the following criteria are ineligible to 
participate in the study:  
1. Malignant tumors other than colorectal adenocarcinomas (current or within the previous five years), with the exception for curatively treated non -
melanoma skin cancer or in situ carcinoma of the cervix.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 9   2. Less than 6 months between randomization and completion of the last anti -
cancer treatment (chemotherapy/radiotherapy/immunotherapy, etc.). (NB: 
Rectal cancer treatment shorter than 8 weeks of chemo/radiation therapy is allowed.)  
3. Confirmation of progressive disease within 6 months after completion of prior adjuvant anti -cancer treatment.  
4. Indication for any metastatic Colo -rectal Cancer ( mCRC ) surgery or anti- cancer 
treatment other than study treatment.  
5. Prior treatment with arfolitixorin . 
6. Indication for treatment with a 5 -FU analogue, or 5 -FU for a condition other 
than mCRC.  
7. Known Dihydropyrimidine Dehydrogenase Deficiency  (DPD ) deficiency.  
8. Known or suspected central nervous system  (CNS)  metastases. 
9. Unresolved bowel obstruction, uncontrolled Crohnâ€™s disease, or ulcerative colitis.  
10. History of cardiac disease with a New York Heart Association Class II or greater, 
congestive heart f ailure, myocardial infarction, or unstable angina at any time 
during the 6 months prior to randomization, or serious arrhythmias requiring 
medication for treatment.  
11. Current CTCAE â‰¥ grade 3  diarrhea.  
12. Current chronic infection or uncontrolled serious illness causing 
immunodeficiency.  
13. Known or suspected hypersensitivity or intolerance to arfolitixorin , LV, 5 -FU, 
oxaliplatin, or bevacizumab.  
14. Breastfeeding patients.  
15. Patient who received investigational drugs in other clinical trials within 28 days, or 5 h alf-lives of the investigational drug, prior to randomization.  
16. Patient with serious medical or psychiatric illness likely to interfere with 
participation in this clinical study.  
17. Ongoing drug or alcohol abuse , as deemed by the I nvestigator. 
18. Any condition that, in the opinion of the Investigator, could compromise the patient's safety or adherence to the study protocol.  
19. Involvement, or related to people involved in the planning or conduct of the study (applies to both Isofol Medical AB (publ) staff and staff at the study site)  
20. Surgery (excluding previous diagnostic biopsy) in the 28 -day period before 
randomization  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 10 Interventions  Investigational Medic inal Product (IMP)  
â€¢ Study drug : Arfolitixorin  ([6R] 5,10- methylenetetrahydrofolic acid) is 
formulated as a lyophilized white to light yellowish or light beige powder 
containing 100 mg arfolitixorin  per vial.  Each vial of arfolitixorin  must be 
reconstituted with 10 m L water  for injection  before admin istration as 
rapid IV bolus injections.  
â€¢ Comparator : Leucovorin (LV; folinic acid) 400 mg/m2 IV infusion.   
Non- investigational medicinal products  
â€¢ 5-FU, oxaliplatin, and bevacizumab.  
Treatment regimens  
Eligible and consenting patients will be randomized 1:1 to one of two treatment groups (A and B) , administered according to  the treatment regimens described 
below. Each new treatment cycle should start on day 14 (+ 7 days) after the 
previous treatment cycle (unless delayed due to toxicity): 
Group A ( ARFOX + bevacizumab): 
â€¢ Bevacizumab 5 mg/kg, IV infusion in accordance with the label   
â†“ followed by  
â€¢ Oxaliplatin 85  mg/m
2 IV infusion in accordance with the label   
â†“ followed by  
â€¢ 5-FU 400 mg/m2 IV bolus ( 2â€“4 minutes ) 
â†“ followed by (30 minutes (Â± 5 minutes) after 5 -FU bolus)  
â€¢ Arfolitixorin 60  mg/m2 rapid IV bolus (less tha n 3 minutes)  
â†“ followed by  
â€¢ 5-FU 2400  mg/m2 continuous IV infusion over 46 hours  
â†“ followed by (30 -60 minutes after first arfolitixorin bolus ) 
â€¢ Arfolitixorin  60 mg/m2 rapid IV bolus (less tha n 3 minutes)  
 
Group B (modified FOLFOX -6 + bevacizumab):  
â€¢ Bevacizumab 5 mg/kg, IV infusion in accordance with the label   
â†“ followed by  
â€¢ Oxaliplatin 85  mg/m2 IV infusion in accordance with the label  
â†“ followed by * 
â€¢ LV 400  mg/m2 IV infusion  
â†“ followed by  
â€¢ 5-FU 400 mg/m2 IV bolus ( 2â€“4 minutes ) 
â†“ followed by  
â€¢ 5-FU 2400 mg/m2 continuous IV infusion over 46 hours  
*Oxaliplatin and LV may be administered at the same time through two different injection ports. NB: Oxaliplatin and LV must not be mixed.  
The doses of arfolitixorin  and LV should not be adjusted. 5- FU and LV should be 
administered separately to avoid the formation of a precipitate. Following a 
treatment -related adverse event the doses of 5 -FU, oxaliplatin, and bevacizumab 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 11 may  be adjusted or delayed in accordance with the label  and sect ion 6.3.4  in the 
protocol. Oxaliplatin cannot be substituted  but caution should be taken regarding 
toxicity and in case of toxicity, dose modifications (decrease in infusion rat e and/or 
dose reductions) according to label should be performed . For patients with 
platinum hypersensitivity, pre -medication with IV dexamethasone, 
chlorphenamine, and ranitidine can be given at the Investigatorâ€™s discretion.  
Prohibited concomitant therap ies 
Treatment with nucleoside analogues, known DPD inhibitors, additional anti -
cancer treatment, additional experimental medications , and radiation therapy are  
prohibited during the screening period  or in conjunction with the IMP.  
Study visits  Study visits include a screening visit, a randomization/baseline visit, regular 
treatment visits every 2 weeks, and CT/MRI assessments every 8 weeks.  
Treatment visits will continue until progressive disease ( PD) as assessed by the 
Investigator. The assessment visits will continue until centrally confirmed PD 
according to RECIST 1.1  criteria. An end of treatment visit will occur following PD 
or premature discontinuation of IMP. Follow -up (visit or phone call) for OS occurs 
every 12 weeks thereafter until en d of study.     
Study design  This is a randomized, multicenter, parallel- group, Phase III study to compare the 
efficacy of arfolitixorin  versus LV in patients with  advanced CRC treated by 5 -FU, 
oxaliplatin, and bevacizumab . 
Patients will be randomized in a 1:1  ratio to either the investigational arm 
(arfolitixorin ) or the comparator arm (Leucovorin), following the completion of all 
screening assessments and after confirmation of their eligibility , using a stratified 
permuted block randomization. Randomization will be stratified for the following 
baseline factors :  
â€¢ Geographic region (Europe versus  North America  versus  Australia versus  
Japan ) 
â€¢ Primary tumor location ( left colon  versus  right colon versus  rectal cancer) 
â€¢ Previous neo-adjuvant/ adjuvant CRC treatment  (yes versus  no) 
 
Tumor  evaluations, based on CT/MRI , will be performed at baseline and every 8 
weeks  until PD  by a  blinded independent central  review committee ( according to 
RECIST 1.1 definitions ).  All patient s will be treated according to the study protocol 
until PD as determined by the Investigator , unless prematurely discontinu ed from  
treatment for any reason. A BICR review will be performed to assess  all tumor 
responses and progression  in accordance with RECIST 1.1 definitions . BICR 
committee members  will be blinded to all treatment data and perform their 
reviews in closed -meeting sessions. All activities and processes related to the B ICR 
will be outlined in the BICR Charter.  
Final analysis  of ORR  and PFS will be done when at least 235 PFS events are 
reached . An adaptive design allows for a re -estimation of the sample size based on 
interim results. If the sample size is increased to 660 patients, the final analysis of 
ORR and PFS will be done when approximately 450 PFS events have been observed. 
All patients will be followed for OS after end of treatment ( regardless whether due 
to discontinuation/withdrawal or PD) until 60% OS events have been reached .    
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 12 Premature 
discontinuation of treatment  Patients may withdraw consent to participation in the study or voluntarily 
discontinue treatment with IMP at any time without providing a reason and 
without any prejudice to future treatment.  The Investigator  may also, at his/ her 
discretion, discontinue IMP at any time if it is in the best interest of the patientsâ€™ 
well- being.  The Sponsor  can instruct the Investigator to discontinue IMP  (e.g.  due 
to severe non -compliance with the protocol ). Patients discontinuing treatment 
will be asked to continue with follow -up assessments, including ongoing CT/MRI 
assessments until centrally confirmed PD  or end of study . 
Data and Safety 
Monitoring Board (DSMB)  An independent DSMB will be established and regularly  monitor the safety  profile 
and study progress to ensure that the study is being conducted with the highest safety, scientific and ethical standards.  The  DSMB Charter specifies  the DSMB 
procedures and constitution, statistically derived 
interim analysis decision 
guidelines , as well as time points for DSMB evaluations. Recommendations from 
the DSMB to the Sponsor will comprise, in addition , increasing sample size, as well 
as early termination of the study or any other relevant recommendations.  
An interim analysis  will be performed  when 16 -week BICR evaluation has been 
performed for the 330th patient . The objective of the interim  analysis is to 
calculate  the conditional power  for both ORR and PFS  to guide  continuing the 
study as planned or increasing the sample size.  The g uidelines for sample size 
increase decisions are defined in the DSMB charter and protocol section 9.4.6 .  
There is no intention to claim efficacy for ORR or PFS at this stage. The interim 
results will only serve to guide the decision rules regarding sample size re -
estimation. Results of this analysis will remain blinded to everyone, except the DSMB . Regardles s of the efficacy results of the interim analysis, the trial will 
continue to accrue patients, until the total planned sample size is reached.  
Number of planned patient s & 
replacement  Approximately 490 patients will be randomized 1:1 to arfolitixorin or LV at 
approximately 80 -100 study sites in Europe, Canada, the United States , Australia 
and Japan. Patients randomized but prematurely discontinuing before receiving any study treatment will be replaced.  
The sample size calculation is based  on the following assumptions:  
â€¢ The ORR is 60% in Group A  
â€¢ The ORR is 45% in Group B  
For a two -sided test with ð›¼ð›¼=0.05 and a power of 80%, 440 patients need to be 
treated to detect this difference, and also allow for an interim analysis on 330 patients. Adjustment of the significance level in the interim analysis and final analysis has been performed, using a Rho spe nding function, with Ï=5 for the 
primary endpoint (ORR) at the interim analysis, so that the overall 2 -sided 
significance level does not exceed the desired ð›¼ð›¼ of 0.05. Although significance will 
not be claimed based on the interim results, this small alpha  spending is foreseen 
to take into account the interim look at the results for ORR  and PFS . 
Initially, approximately 440 were planned to be randomized. However, Japanese 
authorities requested that approximately 12.7% of the total study population are 
enrol led from Japan. For this reason, additional patients from Japan were 
randomized. In the end a total of 490 patients were randomized. This decision to 
randomize extra Japanese patients was made  before the interim analysis. The 
decision to include the Japane se patients in the ITT population (see Section 9.2.2) 
for the primary efficacy analysis was made  after the interim analysis. T he addition 
of extra Japanese patients leads to a statistical power greater than 80%  for ORR . 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 13  Statistical 
Methods  
 A statistical analysis plan will be in place before inc luding patients in the study.  
The analysis will be stratified for the following factors:  
â€¢ Geographical region (Europe versus  North America versus  Australia versus  
Japan ) 
â€¢ Primary tumor location (left colon  versus  right colon  versus  rectal cancer)  
â€¢ Previous neo-adjuvant/ adjuvant CRC treatment  (yes versus  no) 
All efficacy analyses will be performed  on both the ITT  and the per -protocol 
analysis set s. The ITT analysis  will be the primary basis for int erpreting study 
results . 
ORR will be analyzed using a Cochran -Mantel -Haenszel test (CMH), stratified for 
the stratification factors used for randomization (geographic region, primary 
tumor location and previous neo -adjuvant/ adjuvant CRC treatment) . 
PFS, DOR  and OS will be analyzed using Kaplan -Meier curves, the logrank test and 
a stratified Cox proportional hazards model, using the same stratification factors as for randomization (geographic region, primary tumor location and previous neo-adjuvant/adjuvan t CRC treatment) . The assumption of proportional hazards 
will be tested. For AEs absolute and relative frequencies will be presented in total and by system organ class/preferred term, intensity , and relatedness.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 14 1.2 SCHEMA  
 
  
1:1 Randomi zation  
  
Group A  
arfolitixorin, 5 -FU, 
oxaliplatin +  
bevacizumab 
 
Group B  
Leucovorin, 5 -FU, 
oxaliplatin +  
bevacizumab 
 
Interim analysis 
when 330 patients  
are evaluable for 
response after at 
least 16  weeks of 
treatment, 
analyzing both ORR  
and PFS. 
  
Depending on the 
conditional  power s, 
the trial will either 
continue as 
planned, or the 
sample size will be 
increased for a 
total of 660 
patients.  
Final analysis of 
ORR and PFS to 
be performed 
when at least 
235 PFS events  
have been 
observed.  
 
If the sample size 
is increased to 
660 patients the 
analysis will be 
performed when 
450 PFS events 
have been 
observed.   
Follow -up for survival 
every 12 weeks  until  
60% of patients have 
reached OS . 
Imaging 
evaluations 
done  at baseline 
and every 8 
weeks 
throughout the 
study.  
 
Confirmatory 
scans performed 
8 weeks after 
response.  
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 15 1.3 SCHEDULE OF ACTIVITIES (SOA)  
 
Table 1: Schedule of A ctivities (SOA)  
 
 PRE-TREATMENT  TREATMENT PERIOD  END OF TREATMENT FOLLOW -UP 
Screening  
 Administer IMP  Assessment 
visit  Administer IMP  Assessment 
visit  End of treatment 
visit Follow- up visits 
until centrally 
confirmed PD Survival  follow- up 
 Cycle 1  
 Cycles 2 -4  Cycles 5  - PD or 
discontinuation    Only patients 
prematurely 
discontinuing IMP 
prior to  centrally 
confirmed PD All patients  
 Timing   Day 1  
Baseline  14 days 
after 
previous 
admin 
visit  Week 8  from 
day 1  14 days after 
previous admin 
visit  Weeks 16, 
24, etc. from 
day 1  Within 30 days after 
last dose of IMP and 
before start of new 
anti-cancer 
treatment  Every 8 weeks 
from end of 
treatment visit 
until  centrally 
confirmed PD Every 12 weeks 
after centrally 
confirmed PD 
until death  or end 
of study 
CSP 
Section  Visit window  Day -28 to  
Day -1 -3 daysa,f +7 days  Â±7 days  +7 days  Â±7 days   
Â±7 days  Â±7 days  
Screening procedures  
10.1.1  Informed consent  X         
8.3 Patient Study ID  X         
5.1/5.2 Eligibility criteria  X X        
8.3 Demographics/medical history  X         
6.4 Randomization   Xa        
General procedures  
6.6 Concomitant therapy  X X X X X X X   
8.2 Physical examination  X X  X  X X   
8.2 Vital signs  X X X X X X X   
8.2 Height  X         
8.2 Weighte X X X X X X X   
8.2 Biopsy  available for Pharmacogenetics  X         
6.1/6.2 Administer and record study treatment   X X  X     
6.6 Record other anti- cancer treatment        X X X 
8.1 ECOG  X X  X  X X X  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 16  
 PRE-TREATMENT  TREATMENT PERIOD  END OF TREATMENT FOLLOW -UP 
Screening  
 Administer IMP  Assessment 
visit  Administer IMP  Assessment 
visit  End of treatment 
visit Follow- up visits 
until centrally 
confirmed PD Survival  follow- up 
 Cycle 1  
 Cycles 2 -4  Cycles 5  - PD or 
discontinuation    Only patients 
prematurely 
discontinuing IMP 
prior to  centrally 
confirmed PD All patients  
 Timing   Day 1  
Baseline  14 days 
after 
previous 
admin 
visit  Week 8  from 
day 1  14 days after 
previous admin 
visit  Weeks 16, 
24, etc. from 
day 1  Within 30 days after 
last dose of IMP and 
before start of new 
anti-cancer 
treatment  Every 8 weeks 
from end of 
treatment visit 
until  centrally 
confirmed PD Every 12 weeks 
after centrally 
confirmed PD 
until death  or end 
of study 
CSP 
Section  Visit window  Day -28 to  
Day -1 -3 daysa,f +7 days  Â±7 days  +7 days  Â±7 days   
Â±7 days  Â±7 days  
Efficacy assessments  
8.1 Plasma PK  sample   Xb Xb       
8.1 CT-scan/MRIc X   X  X X X  
8.1 PRO EQ-5D  X  X  X X   
8.1 Survival Status          Xg 
Safety assessments  
8.4 AEs   X X X  X X Xd Xd  
8.2 PRO  CTCAE  X X X  X X   
8.2 Hematology and clinical chemistrye Xf  X  X  X   
8.2 Urinalysise Xf  X  X  X   
8.2 ECGh  X X       
8.2 Pregnancy test  Xf      X   
a Randomisation can occur  on the same day as  study  treatment initiation , or up to 3 days before study treatment initiation.  Study t reatment must be initiated within 28 days from start of screening.  
b Plasma PK samples  will be collected during Cycle 1 and Cycle 2 . 
c CT-scans/MRIs must be performed on thorax, abdomen and pelvis. Post -randomisation CT -scans/MRIs should be performed every 8 weeks (Â±7 days ) from Day 1  to PD confirmed by BICR . End of Treatment visit scans will be taken if the 
previous scan is >14 days.  
d AEs are to be recorded until the day of the End of Treatment Visit . After the End of Treatment Visit , only S AEs related to study specific procedures or considered to be at least possibly related to study drug should be recorded.  
e Laboratory , urine samples  and weight  are to be collected according to local practice  (7 days before study treatment) .  The laborator y and urinalysis reports must be obtained and reviewed prior to administration of chemotherapy for each 
cycle.   
f Haematology, clinical chemistry, urinalysis, and pregnancy testing must be performed within  7 days prior to study treatment initiation and must be assessed before randomi zation  
g Survival follow -up visit could be conducted either by phone. ordinary visits, hospital records or other means found suitable. 
h 12-lead ECG should be performed  during administration visits 1 -4.  Directly p rior to and 10 min  (Â±5 min)  after each arfolitixorin dose , and directly prior to and 10  min (Â±5 min) after initiation of Leucovorin infusion , during administration 
visits 1 -4.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 17 2  INTRODUCTION  
 
2.1 STUDY RATIONALE   
 
2.1.1  AD VANCED  COLORECTAL CANCER  
Colorectal cancer (CRC) is the third most common cancer in men (10% of the total) and the second in 
women (9.2%), with over 1.3 million cases (746 000 men and 614 000 women) reported worldwide 
during 2012. The geographic incidence of CRC varies widely acro ss the world, and the geographical 
patterns are very similar in men and women. Incidence rates vary ten -fold in both sexes worldwide, 
the highest estimated rates being in Australia/New Zealand (the age standardized  rate ( ASR) 44.8 and 
32.2 per 100 000 in m en and women respectively), and the lowest in Western Africa (4.5 and 3.8 per 
100 000). The incidence increases with age and is highest amongst the elder ly, i.e. , 60-64 years: 67.4; 
65-69 years: 95.1; 70- 74 years: 127.8; and â‰¥ 75 years: 196.2 per 100  000 [1]. 
Approximately 40 -50% of the affected patients develop metastatic disease and more than half a 
million deaths are reported annually as a consequence of CRC [2] . CRC accounted for 694 000 deaths 
worldwide solely during 2012 (8.5% of total cancer deaths ) [1]. 
 
2.1.2  C URRENT STANDARD OF CARE  
CRC patients are usually treated surgically and, in most circumstances, with curative intent. Surgery, 
in fact, remains the primary modality of treatment for malignancies of the lower gastrointestinal tract, 
and standard resection is the only therapy r equired for early -stage cancer [3].  
As the stage of the tumor advances, in terms of depth of penetration and lymph node involvement, the chance of cure with surgery alone diminishes and the rate of local recurrence increase. In  such 
cases, surgery may either be combined with adjuvant treatment or be performed for palliative control of symptoms only.  
Standard first -line systemic therapy for metastatic  colorectal cancer (mCRC) , in accordance with 
current European Society for Medical Oncology (ESMO) guidelines, is chemotherapy with 5 -
fluorouracil (5 -FU) + Leucovorin (LV) + oxalip latin/irinotecan Â± bevacizumab [4] .  
2.1.2.1  CY
 TOTOXIC AGENT S 
The backbone of ï¬rst- line palliative chemotherapy alone, as well in combination with targeted agents, 
consists of a ï¬‚uoropyrimidine  (FP; intravenous [IV] 5- FU or the oral FP  capecitabine ) in vari ous 
combinations and schedules  [5, 6] .  
LV is a part of a standard treatment regime n for advanced CRC in combination with the anti- metabolite 
5-fluorouracil (5 -FU) as it greatly improves the efficacy of 5 -FU [7, 8]. Arfolitixorin  is an endogenous 
folate -base d compound designed to replace LV   
The oral FP capecitabine is an alternative to IV 5- FU/LV [7, 8]. Combination  chemotherapy with 5 -
FU/LV/oxaliplatin (FO LFOX) or 5 -FU/LV/irinotecan (FOLFIRI) provides higher response rates (RRs),  
longer PFS and better survival than 5FU/LV  alone  [5, 6, 9, 10 ]. FOLFOX and FOLFIRI as chemotherapy  
alone have similar activity and are both partners for biologics but  have a different toxicity proï¬le: 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 18 more alopecia and, in  most trials, more severe diarrhea for irinotecan and more polyneuropathy  for 
oxaliplatin [5, 11]. They also have potentially  differe nt interactions with biologicals.  
2.1.2.2  BI OLOGIC AGENT S 
Bevacizumab, an antibody that binds circulating VEGF -A, increases the activity of any active cytotoxic 
regimen. Bevacizumab has been shown to improve RR, PFS and/or OS when used as first -line 
treatment in c ombination with 5 -FU/LV/irinotecan and in combination with 5 -FU/LV or capecitabine 
alone [12, 13, 14, 15]. Bevacizumab has also been shown to improve the PFS but not RR or OS in 
combination with an FP plus oxaliplatin in t he ï¬rst -line treatment of mCRC [16, 17]. Bevacizumab is 
usually continued in combination with a cytotoxic agent/combination until PD or toxicity.  
2.1.3  M ECHANISM OF ACTION OF ARFOLITIXORIN  
The Active ingredient of the Drug substance is arfolitixorin or [6R]- 5,10- methylene- tetrahydrofolic acid 
([6R] -5,10- MTHF). It is present as such in the reconstituted solution from the Drug product 
lyophilizate . The principal mechanism of action is ultimately the same for arfolitixorin as for LV or L -
LV [18], used together with 5 -FU as [6R]-5,10 -MTHF is the key endogenous active metabolite of these 
drugs, and is a necessary co -substrate in the synthesis of deoxy -thymidine monophosphate (dTMP) 
from deoxy -uridine monophosphate (dUMP), a reaction catalyzed by the enzyme thymidylate 
synthase (TS). dTMP is in turn a necessary substrate for DNA synthesis and repair and is thus essential 
for cell division and life [19] . Indeed, the antitumor agent 5 -FU is known to e xert its cytotoxic activity, 
to a major extent, through inhibition of the TS enzyme  [18].  
For either synthesis of dTMP from dUMP via TS catalysis, or inhibition of TS by 5 -FdUMP (a metabolite 
of 5 -FU), a ternary complex is formed between TS, [6R] -5,10- MTHF, and the respective third 
component, either dUMP or 5- FdUMP.  In the (normal) synthesis situation dUMP picks up the 
methylene (the 1 -carbon unit) from [6R] -5,10- MTHF while bound in the ternary complex to form 
dTMP. dTMP is then released during complete decomposition of the ternary complex. The transformation of dUMP into dTMP occurs simultaneously with a 5 -H abstraction from the dUMP 
molecule. If instead 5 -FdUMP has become bound into the ternary complex, the 5 -F atom cannot be 
abstracted. The ternary compl ex instead remains stable and the TS enzyme is inhibited. This is because 
the enzyme TS cannot be released from the 5F -containing ternary complex for a renewed catalytic 
reaction [18].  
The relatively stable FdUMP - containing â€œinhibitoryâ€ ternary complex c an, however, release its [6R] -
5,10 -MTHF moiety and initiate complete decomposition of this ternary complex. Since the release 
step is an equilibrium reaction, increased concentration of [6R] -5,10- MTHF will stabilize the 
(â€œinhibitoryâ€) ternary complex and t hereby strengthen the TS inhibition. This means that the higher 
the concentration of [6R] -5,10 -MTHF , the higher the stability of the F dUMP -containing â€œinhibitoryâ€ 
ternary complex.   
In vivo tetrahydrofolic acid (THF) and 5 -methyl -THF are rapidly formed after administration of both 
arfolitixorin and LV/L -LV and these two metabolites together constitute a â€œmetabolite poolâ€, which 
can re -generate [6R] -5,10 -MTHF [18]. Plasma concentration data from a PK/PD study, showing very 
high (transient) plasma levels of [ 6R]-5,10 -MTHF immediately after the administration of arfolitixorin 
and hardly any after L -LV [2 0].  These much higher levels during the first 30 minutes after arfolitixorin 
may be particularly relevant for efficacy. Our selected  dose regime for arfolitixo rin, involving two bolus 
doses separated by 30 minutes, is thought to be supported by the PK/PD situation.  
Arfolitixorin, [6R]- 5,10- MTHF,  circumvents the genetically influenced multistep metabolic activation 
necessary for biological activity of LV/L -LV and consequently, is thought to be efficacious in a larger 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 19 proportion of patients and with significantly less inter- and possibly intra-individual variability [18]. 
This together with all the direct PK/PD advantages  is thought to serve to make arfolitixorin a  better 
candidate for improved outcome of 5 -FU-based chemotherapy regimens in advanced CRC provided 
that an acceptable benefit/risk ratio can be maintained.   
 
   
2.2 BACKGROUND   
 
2.2.1  N ON -CLINICAL BACKGROUND  
The nonclinical data are described in the current version of arfolitixorin  Investigatorâ€™s brochure . 
Arfolitixorin  has been evaluated in preclinical GLP (Good Laboratory Practice) rat and dog studies. In 
summary, twice daily IV administration of arfolitixorin  for up to 28 days is well tolerated in rats at 
doses up to 100 mg/kg/day and in beagle dogs at doses up to 50 mg/kg/day.  
The Active Pharmaceutical Ingredient (API) of arfolitixorin has also been evaluated in various  non-GLP 
mouse models in combination with different anti- metabolites such as p emetrexed  and 5 -FU. No 
indications of safety issues related to arfolitixorin  have been observed in these studies.  
A 13-week  (3 months) toxicology program in rats and beagle dogs concluded that the twice daily 
intravenous administrations of arfolitixorin  to Sprague -Dawley rats at doses of up to 300 mg/kg (150 
mg/kg b.i.d) for 13 weeks was well  tolerated, causing non -adverse histopa thological changes at the 
site of administration and the  spleen (extramedullary hematopoiesis) The majority of findings showed 
clear evidence of recovery during the two -week off -dose period, and those  without recovery were all 
considered non -adverse. There fore, the highest dose of 300 mg/kg  (150 mg/kg b.i.d) was considered 
to be the no -observed -adverse -effect level (NOAEL).   
In Beagle dogs for a 13 weeks administration in cycles of 5 out of 7 days during 3 weeks on and 1 week 
off was well tolerated and res ulted in findings in the kidneys of females, and a non -toxicologically 
relevant higher ALT and AST activity and an increase in urea and creatinine level, at 375 mg/kg/day. 
All renal changes had resolved after a 2 -week recovery period. Therefore, the dose o f 100 mg/kg/day 
arfolitixorin  was considered the NOAEL (No Observed Adverse Effect Level).  
2.2.2  CL INICAL BACKGROUND  
The complete clinical data are described in the current version of the arfolitixorin I nvestigatorâ€™s 
brochure.  
One phase I/II clinical trial with arfolitixorin  in patients diagnosed with operable CRC was performed  
with the aim of comparing  PK/PD profiles in plasma, tumors, and tumor  adjacent mucosa . In this 
clinical trial (ISO -CC-002), 60 or 200 mg/m2 of arfolitixorin  or L-LV was administered as single doses 
prior to surgery . Thirty -two patients were included in this trial, of whom 16 were exposed to  
arfolitixorin . The report from Clinical Trial ISO -CC-002 has been finalized and the results have been 
published  [2 1]. The study explored four folate metabolites: [6R] -MTHF, [6S]-5- methyl -
tetrahydrofolate (5 -methyl -THF), and [6S]-5-THF (THF). The distribution/PK results from the final 
report show that arfolitixorin  administration resulted in higher levels o f [6R] -MTHF and THF in tumors 
and the surrounding mucosa than did L -LV. Arfolitixorin  to L-LV ratios in the tissues were 2.5 -4.0 for 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 20 [6R]-MTHF and 2.4 -5.6 for THF. Arfolitixorin  and L -LV administration resulted in [6S] -5-methyl -THF 
levels of the same magnitude in tumors and the surrounding mucosa. Arfolitixorin  and L -LV gave 
similar concentrations of [6S]-5- methyl -THF in plasma.  
In another phase I/II clinical trial in 24 patients with operable rectal cancer (ISO -MC-091) arfolitixorin  
was administered at a dose of 10, 50, 100, or 500 mg/m2 once every week  for 10 weeks in combination 
with Pemetrexed in  a neo -adjuvant setting.  The primary objective was to evaluate the feasibility of 
arfolitixorin  and Pemetrexed as neo -adjuvant treatment and to identify the optimal dose of 
arfolitixorin . Secondary aims were to evaluate pathological complete response rate, sphincter- saving 
surgery, and levels of arfolitixorin  and its metabolites in tumors, normal mucosa and plasma. The st udy 
was terminated prematurely after four of the five intended doses of arfolitixorin  had been 
administered (10, 50, 100, and 500 mg/m2). The results obtained by then did not indicate any 
improvement in Pemetrexed efficacy with any dose level of arfolitixorin  and it was concluded that no 
further information would be gained by administering the 200 mg/m2 dose. The findings on safety and 
adverse events (AEs) have been published  [22] . There were no AEs in the study that could specifically 
be ascribed to arfolitixorin .  
Another clinical trial, ISO -MTX -003, with arfolitixorin  as a rescue agent after high dose methotrexate  
(HDMTX)  administration in osteosarcoma patients has  been completed. ISO -MTX -003 was a multi-
center study designed to (i) investigate the safety of arfolitixorin  rescue therapy, (ii) identify a 
recommended dose for further study, (iii) and evaluate the feasibility of arfolitixorin as rescue therapy 
for HDMTX treatment. Eight (8) patients in two dose cohorts, 15 mg/m2 and 7 .5 mg/m2 were exposed 
to arfolitixorin . The study findings suggest that the arfolitixorin dose of 15 mg/m2 works as rescue 
treatment at least as well  as the standard  of care  (with calcium folinate) of 15 mg/m2 while the lower 
arfolitixorin  dose of 7.5 mg/m2 seems to involve a slightly lower recue ability in relation to standard  
of care . The dose of 15 mg/m2 was selected fo r further clinical development.  
Yet another trial in colorectal cancer has been initiated, the ISO -CC-005.  The trial investigates the 
tolerabilit y of arfolitixorin  in patients with stage IV CRC simultaneously treated with 5 -FU alone or 
together with oxaliplatin (85 mg/m2) or irinotecan (180 mg/m2) and also to define a dose for 
subsequent trials. Toxicity will be evaluated for four dose levels (30, 60, 120 and 240 mg/m2). The 
selected dose from the arfolitixorin , 5-FU and oxaliplatin treatment arm will then be evaluated for 
safety together with bevacizumab  prior to study start . 105 patients in t his trial have been exposed to 
arfolitixorin . 
According to IB version 14, dated 1 Oct 2021, seven hundred and thirteen ( 713) p atients  have been 
enrolled in Isofol Medical ABâ€™s clinical development program and  four hundred and twenty ( 420) have 
received at least one administration of arfolitixorin in doses of 7.5 to 500 mg/m2 alone or in 
combination with different cytostatic agents. The 420 patients include  388 patients with rectal/colon 
cancer, 8 patients with osteosarcoma and 24 adult  healthy male subjects . A total of 226 serious 
adverse events (SAEs) have been reported for patients exposed to arfolitixorin, 25 of which were 
assessed as related to arfolitixorin.   
Consistent with the outcomes reported from previous studies, in particular ISO -CC-005, a revie w of 
reported events in study ISO -CC-007 to date indicates that fatigue and gastrointestinal adverse events 
(AEs), such as nausea and diarrhea, were the most commonly reported AEs among those patients exposed to arfolitixorin.   
The collected knowledge on arfolitixorin indicates that the drug is safe and well tolerable at all doses tested (7.5 to 500 mg/m
2). Treatment emergent AEs are often attributable to the co -administered 
chemotherapy agents rather than to arfolitixorin itself, in fair agreement with th e known safety 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 21 profiles for other folates. The results show that treatment with the chosen Selected phase 2 dose 
(SP2D) 120 mg/m2 arfolitixorin is safe and feasible in dosing settings similar to the well- established 
mod -FOLFOX -6 and FOLFIRI.  
Based upon ex isting non -clinical and clinical data to date, there are no safety concerns identified.  
2.3 RISK/BENEFIT ASSESSMENT    
 
2.3.1  KN OWN  POTENTIAL RISKS  
No toxicity directly related to arfolitixorin  was observed in toxicity studies performed in rat and dog.   
In a healthy volunteer study (ISO -FF-001) to investigate QT effects , 33 subjects  were randomized  to 
placebo (n=9) and three doses of  arfolitixorin , given as a 2 -minute bolus injection in the foll owing 
doses: 200 mg/m2 (n=8); 350 mg/m2 (n=8); or 500 mg/m2 (n=8). The study data indicate that in relation 
to baseline, arfolitixorin causes a dose -dependent increase in QTcF that is transient. For the lowest 
dose level 200 mg/m2 the effect is small and not considered to add risks or warrant increased 
surveillance for patients . 
Safety data from two initial investigations in CRC patients show no evidence of any safety concerns 
for patients after either single high -doses or multiple doses of arfolitixorin .  These clinical data indicate 
that arfolitixorin , in doses of up to 500 mg/m2are well tolerated as bolus IV administration in CRC 
patients.   
Arfolitixorin , in doses of 30, 60, 120, or 240 mg/m2, were administered to CRC patients in combination 
with 5-FU every 2 weeks for at least 8 weeks in a Phase I/II dose -finding and safety study (ISO -CC-005).  
Interim data from this study indicate that all doses are well tolerated with no indications of safety concerns.  
Further details from the non -clinical and clinical studies can be found  in the Investigatorâ€™s Brochure 
(IB). 
2.3.2  KN
OWN POTENTIAL BENEFITS  
Arfolitixorin is the active metabolite of LV and in contrast to LV does not require genetically regulated enzymatic activation. There is a statistically significant correlation between the level of expression of 
certain key genes and the rate of metabolic activation, as measured by tissue concentrations of [6R] -
MTHF [20]. The level of expression of folate -relevant genes correlates with outcome and survival in 
advanced CRC  patients treated with 5 -FU and folates. Approximately two  third s of advanced CRC  
patients fall into the category of low gene expression having a worse prognosis  [23]. 
It has been demonstrated that the administration of arfolitixorin  will result in greater bioavailability 
and higher intracellular concentrations of the active metabolite  than does LV administration in all 
patients, as several metabolic steps are bypassed by arfolitixorin  administration and varying genetic 
profiles are rendered unimportant  [23] . Further it is anticipated  that arfolitixorin  may reduce potential 
interpatient  variability and as a consequence allow for safe and more adaptable and predictable 
treatments. The hypothesis is therefore that administration of arfolitixorin  compared to LV in 
combination with 5 -FU will result in better efficacy.  
2.3.3  AS
SESSMENT OF POTENTIAL RISKS AND BENEFITS  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 22 Arfolitixorin  is expected to be more effective than LV  in potentiating the effect of 5 -FU, particularly in 
patients with low folate -relevan t gene expression . An exploratory endpoint  of this study is to compare 
the impact of certain folate transportation and metabolism related genes on treatment outcome for 
arfolitixorin  and LV, to establish the magnitude of the hypothesized improvemen t.  
To m inimize the number of patients exposed to the investigational drug, the design of the study is 
adaptive, and contains interim analysis and a final analysis (see section  9.4.6). The interim analysis 
includes an opportunity to increase the sample size of the trial adaptively, based on the difference in the primary endpoint results.  
A DSMB  consisting of at least thre e experienced  members including at least an oncologist and one  
biostatistician will be appointed to review, on a regular basis, accumulating safety data as well as efficacy data according to the interim analysis plan. The DSMB  will review unblinded data that will not 
be shared with anyone else (Sponsor or Investigators). At each of their meetings, the DSMB  will 
recommend a course of action: stop the trial, amend the trial protocol, or continue the trial unchanged. The DSMB  recommendation will be based on sa fety considerations and, when 
appropriate, on efficacy considerations as outlined in the interim analysis plan.  
The sponsor (or designee) will be responsible to safeguard the ethical and safety interests of the patient s, Investigators and the sponsor; to a ssess the safety of the studyâ€™s interventions; to monitor 
the overall conduct of the study and to protec t its validity and credibility. The sponsor (or designee)  
will meet at predefined times (or also ad hoc, if deemed necessary), to assess at intervals th e progress 
of the clinical study and the critical e fficacy endpoints (e.g. ORR and PFS ) and will decide  whether to 
continue, modify or stop the s tudy for safety.  
The study will be reviewed and not initiated before approval from relevant IRB/ IEC have been 
obtained. The study will also be monitored, according to GCP  and local requirements, securing the 
trial patient sâ€™ well -being and the integrity of data collected.  
The patients in this study will be closely monitored at the participating study sites following the visit schedule (see section  8.3). 
Arfolitixorin  is the active metabolite of the commercially available prodrug LV and is intended as an 
improvement o f established care. T he efficacy is presumed to be as good as or better than that of LV. 
A comparative study is necessary to assess the magnitude of efficacy improvement. The study design, the close monitoring of the study patient  from the I nvestigators, t he DSMB  and the study monitors 
contributes to preserving the well -being of the trial patient s minimizes the risk of study participation.  
2.3.3.1  A
DVERSE EVENTS OF SPECIAL INTEREST   
The hypothesis is that arfolitixorin in combination with 5 -FU will increase tumor cell killing by 
increasing the active metabolites MTHF and THF within the tumor. However, the increases in these metabolites may also occur in the normal tissue. The two tissues that may have increased toxicity with arfolitixorin in combination with 5- FU are bone marrow and the mucous membranes. Therefore, these 
will be monitored and assessed as Adverse Events of Special Interest (AESI) during the trial and by the DSMB.  
Seventy patients have been treated with arfolitixorin in study ISO -CC-005 and are evaluable after a 
30-day cut off from their first dose of therapy across the arfolitixorin dosage administered which 
ranged from 7 patients treated at 240 mg/m
2, 13 subjects treated at 30 mg/m2, 20 patients treated at 
60 mg/m2 and 35 patients treated at 12 0 mg/m2. The incidence of mucositis in the combination of 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 23 arfolitixorin + 5 -FU with or without other chemotherapeutic agentâ€™s ranges from 1 -5% of all reported 
AEs. Similarly, bone marrow adverse events are also between 1 -5% of all reported AEs in in patien ts 
treated with arfolitixorin + 5 -FU combinations. The incidence of either mucositis or bone marrow 
suppression (neutropenia and thrombocytopenia) appear to be similar to what is reported in clinical 
practice for patients treated with FOLFOX + Bevacizumab.   
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 24 3 OBJECTIVES AND ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
Primary    
Overall response rate (ORR)  Best ORR, defined as  the best 
response recorded from the 
start of the study treatment until the end of treatment. All 
responses will be confirmed 8 
weeks after onset of response. All assessments including confirmation of response will 
be performed by BICR.     The antitumor effect 
attributable directly to the drug, not the natural history of the disease.  
Key Secondary    
Progression -free survival (PFS)  PFS, defined as time from 
randomization to first occurrence of tumor progression (RECIST 1.1) assessed by BICR based on CT -
scans/MRIs conducted every 8 weeks after treatment, or 
death from any cause . PFS is a relevant endpoint to 
measure clinical effect as it also includes stable disease.  
Duration of Response (DOR)  The duration of overall 
response ( DOR ) is measured 
from the first time point at 
which  criteria are met for 
complete response (CR ) or 
partial response ( PR) through  
the last time point when 
overall response has been  
objectively doc umented . DOR measures the duration of 
confirmed CR and PR, which is an important aspect of the clinical significance of DO R. 
Secondary    
Overall survival (OS)  OS, defined as time from 
randomization to death from 
any cause.   OS measures potential 
detrimental effects of therapy, 
and possibly a direct benefit.  
Quality of Life  Quality of Life assessed using  
the EQ -5D patient reported 
outcome questionnaire.  PRO EQ -5D measures patients 
self- experienced quality of life.  
Safety and tolerabilit y Number and severity of 
adverse events (AEs), including clinically significant abnormal laboratory findings, regardless of causal relationship to arfolitixorin  or LV . Specific AEs 
will be followed using patient reported outcome questionnaire (NCI PRO  
CTCAE ). Relevant endpoint to measure 
safety and tolerability.  
Patients undergoing curative 
metastasis resection.  Defined as the number of 
patients qualifying for curative To understand study 
treatment effects on 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 25 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
metastasis resection after 
treatment with study drug.  metastasis become curatively 
resectable.  
Exploratory    
Daily living abilities  Daily living abilities as assessed 
by the Eastern Cooperative 
Oncology Group (ECOG) 
Performance Status Scale  Physicians professional 
estimation  of the patientâ€™s 
status . 
To determine the 
pharmacokinetic (PK) characteristics of arfolitixorin 
and LV  in patients with 
advanced CRC  The plasma concentration of 
[6R]-MTHF, methyl -THF, THF, 
will be determined in a limited number of patients in both 
treatment arms . To increase the understanding 
of the study drug, the study treatment and also in relation to the comparator arm . 
To investigate  folate 
metabolism - and 
transportation -related gene 
expression levels in patients with advanced CRC  Gene expression levels of 
folate metabolism - and 
transportation -related genes, 
analyzed by sub -group 
low/high gene expression 
levels .  To increas e the understanding 
of the study drug.  
Recurrence Free Survival (RFS) 
for patients undergoing metastatic resection.  Defined as the time between 
the first surgery with complete removal of the metastasis and recurrence of the disease or 
death from any cause . To increase the understanding 
of disease recurrence after 
metastasis resection . 
  
4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
This is a randomized , multicenter , parallel-group, Phase III study to compare the efficacy of 
arfolitixorin  versus LV in patients with advanced CRC  treated by 5 -FU, oxaliplatin, and bevacizumab. 
To be eligible for the study, patients must have advanced CRC, without indication for resectio n, with 
at least one measurable lesion of metastatic disease according to RECIST 1.1 criteria [24] within 28 
days of randomization . 
Approximately 490 patients will be randomized  1:1 to receive either arfolitixorin  or LV as a component 
of standard first  line therapy for advanced CRC . The study will consist of a screening visit, a 
randomization  visit during which patients will receive their first course of IMP , regular treatment visits 
every 2 weeks thereafter, and CT/MRI assessments every 8 weeks from bas eline. Treatment visits are 
to continue until PD, as identified by the Investigator  based on locally -performed assessment of CT -
scans/MRIs. In the event of PD, Investigators are to discontinue IMP and manage the patient  according 
to local routine. Patients will be followed thereafter until death.   
Randomiza tion minimizes  potential bias. Multiple sites across geographic regions allows for widely  
applicable results. Baseline  factors considered in the randomization  will include :  
â€¢ Geographical region (Europe versus  North America versus  Australia versus  Japan ) 
â€¢ Primary tumor location ( left colon  versus  right colon  versus  rectal cancer) 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 26 â€¢ Previous neo-adjuvant/ adjuvant CRC treatment  (yes versus  no) 
Patient and Investigator blinding is not possible as there is a difference in the color  of the injection 
fluids and  the method of administration. However, as a measure to minimize  any bias arising either 
from the inability to blind patients and Investigator s or from potential inconsistencies in local tumor  
response assessments across study sites, analyses of the tumor  response endpoints will be based on 
blinded, retrospective, centrally -adjudicated assessment of CT -scans/MRIs according to a pre -
specified Image Review Charter.  
An interim analysis will be performed when 16 -week BICR evaluation has been performed for the 
330th patient. The objective of the interim  analysis is to calculate  the conditional power  for ORR and 
PFS to continu e the study as planned or increasing the sample size.  The guidelines for sample size 
increase decisions  is clearly defined in the DSMB charter and in secti on 9.4.6. Regardless of the efficacy 
results of the interim analysis, the trial will continue to accrue patients, until the total planned sample 
size is reached.  
Initially, approximately 440 were plan ned to be randomized. However, Japanese authorities requested 
that approximately 12.7% of the total study population are enrolled from Japan. For this reason, additional patients from Japan were randomized. In the end a total of 490 patients were  randomize d. 
This decision to randomize extra Japanese patients was made  before the interim analysis. The decision 
to include the Japanese patients in the ITT population (see Section 9.2.2) for the primary efficacy 
analysis was made  after the interim analysis.  
The d ecision -making process to terminate a trial early due to evidence of harm or benefit is complex  
and is defined in section 9.4.6. 
4.2 SCIENTIFIC R ATIONALE FOR S TUDY DESIGN  
Standard first -line systemic therapy for mCRC, is chemotherapy with 5 -FU + LV + oxaliplatin/irinotecan 
Â± bevacizumab.  LV is a prodrug of the active subs tance MTHF, which  has a central role in the 
potentiation of the 5 -FU-mediated inhibition of TS and subsequently halting DNA synthesis and cell 
proliferation.  
Arfolitixorin  is the active metabolite of LV and in contrast to LV does not require genetically in fluenced 
multistep metabolic  activation. D istribution results have show n that arfolitixorin  versus LV  
administration of equimolar doses resulted in higher levels of [6R] -MTHF and THF in tumors and the 
surrounding mucosa for arfolitixorin  [20].  
Arfolitixorin  is therefore expected to be more effective than LV, particularly in patients with low folate -
relevant gene expression . Further it is suggested that arfolitixorin  may reduce potential interpatient 
variability and as a consequence allow for safe and more adaptable and predictable treatments. The purpose of this study is to compare arfolitixorin to LV t o establish the magnitude of the hypothesized 
improvemen t.  
The study is designed as a superiority study. To minimize the number of patients exposed to the 
investigational drug, the design of the study is adaptive, and contains interim analysis and a final 
analysis (see section 9.4.6  for details). The interim analysis includes an opportunity to increase the 
sample size of the trial adaptively, based on the conditional power for ORR and PFS . 
Patient and Investigator blinding is not possible as there is a difference in color of the injection fluids  
and the method of administration (intravenous bolus injection versus infusion). However, as a 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 27 measure to minimize any bias arising either from the inability to blind patients and I nvestigators or 
from potential inconsistencies in local tumor response asse ssments across study sites, analyses of the 
tumor response endpoints will be based on blinded, retrospective, centrally -adjudicated assessment 
of CT -scans/MRIs according to a pre -specified Image Review Charter.  
 
 
4.3 JUSTIFICATION FOR DO SE 
 
The mechanism of action and the rationale for combining folate derivatives with 5 -FU is universally 
accepted and applied  [18, 19 ]. In treatment of colorectal cancer with cytotoxic combination s 
comprising 5 -FU together with folate derivatives, the principal role of the folate component is to 
potentiate and prolong the inhibitory effect of 5 -FdUMP (a 5 -FU metabolite) on TS a nd thereby reduce 
the supply of thymidine for DNA synthesis and cell replication whilst maintaining an acceptable clinical  
benef it-risk ratio. Despite universal use of this combination  for decades, the literature is scarce 
regarding systematic studies aiming to define op timal doses of each drug in the combination. Instead 
the focus is on the nature of the diseas e and the intrinsic statistical variance with ensuing large sample 
sizes on one hand and the demand for therapeutic  progress on the other necessitated a different route 
of advancing. The folate predominantly used in this context has be en LV, which requires multistep 
enzymatic  conversion to the active metabolite [6R] -5,10-methylenetetrahydrofolate. In this  pivotal 
study, ISO -CC-007, the logical reference therapy is LV and the reference treatment regimen is  modi fied 
FOLFOX -6 plus bevacizumab, which is a frequently used standard regimen in the treatment of 
advanced CRC  patients. For the experimental arm, the LV infusion of the modified FOLFOX -6 therapy 
is exchanged to arfolitixorin . Arfolitixorin  is however not suitable for infusion due to a short half- life. 
Arfolitixorin is therefore  administered as  bolus injection.  
 The Sponsor has considered the following aspects when selecting the dose for future development of  
arfolitixorin : 
 
1. The Sponsor has  taken previous efforts  by Adventrx Inc  in develop ing the dual 
diastereoisomers [6R,S] -5,10- meth ylenetetrahydrofolate into account. The development 
was unsuccessful  for various reasons, particularly due to the infusion administration of 
[6R,S] -5,10- methylenetetrahydrofolate, which is highly unstable in aqueous solutio n over 
2 hours.  
 
2. Comparison of dose levels with marketed reduced folates (prodrugs of arfolitixorin ) i.e., LV 
and L -LV and failed attempts to develop [6R] -MTHF. LV is and has been used in doses from 
15 mg/m
2 every six hours IV to 1500 mg/m2 every six hours IV as rescue after high dose 
methotrexate treatment  [25, 26]. Furthermore, in combination with 5- FU in colorectal 
cancer, doses from 20 mg/m2 IV to 500 mg/m2 IV over 2 hours every second week have been 
used  [4, 20]. 
 
3. PK and tissue concentra tion data of arfolitixorin  and LV collected from previous studies, i.e. 
the ISO- CC-002 and ISO -CC-005 studies. The results obtained demonstrate that arfolitixorin  
administration leads to much greater exposure and levels of MTHF and THF compared to administ ration of an equimolar L -LV dose. The identified differences in PK/PD with respect to 
[6R]-MTHF and THF levels in tumor, surrounding mucosa, and plasma after administration of 
arfolitixorin  and L -LV suggest that it might be possible to modify the outcome of present well -
established treatments within different cancer therapeutic areas that are based on chemotherapy regimens including folates.  
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 28 4. The amalgamated pre -clinical safe ty experience for arfolitixorin  show s no toxicity or adverse 
effect directly related to arfolitixorin  in either the preliminary or 28 -day toxicity studies 
performed in rats and dogs. At that  time, the highest dose tested was considered to be the 
maximum feasible dose.  Roughly determined, maximu m exposure in rats and dogs was more 
than 50 -fold compared to estimated exposure at 120 mg/m2. The initiated 3 -month toxicity 
studies in the same species are expected to further confirm the safety of arfolitixorin  and will 
also investigate higher concentrations with the aim of reaching the maximum tolerated dose 
(MTD).  
 
5. The arfolitixorin  Investigators Brochure was last updated in 9 July 2018 . Up until 20 August  
2018, arfolitixorin  has been administered to over 145 patients and administered more than 
1000  times in dosages varying from 7.5 to 500 mg/m2 alone or in combination with different 
cytostatic agents.  Results from the ongoing ISO -CC-005 study, designed to investigate the 
tolerability of various doses, has evaluated dose levels of 30, 60, 120 and 240 mg/m2 of 
arfolitixorin  in combination with 5 -FU and oxaliplatin with monitoring of clinical and 
laboratory safety  data. Preliminary results show that arfolitixorin  in a dose range of 30 -240 
mg/m2 is not linked to worsened tolerability compared to historical experience.  
 
6. The main mechanism of action is a folate -enhanced and prol onged inhibition of TS.  Plasma 
deoxyuridine levels ( pdUrd ) is a marker for the global (all cells and organs in the organism) 
inhibition of  TS. The influence on pdUrd of L eucovorin, an equimolar and several incremental 
doses of arfolitixorin  have now been established.  
 Arfolitixorin  gives enhanced levels of pdUrd compared to an equimolar standard dose of L eucovorin 
and a dose dependent increa se of pdUrd with incremental doses of arfolitixorin  which levels off 
between the doses 60 and 240 mg/m
2 BSA. Doses above 120 mg are therefore unlikely to result in 
much higher efficacy and the doses of arfolitixorin of both 60 and 120 m/m2 are deemed adequate 
for efficacy under the above hypothesis.  
The decision to use two  separate injections is supported b y the following data based on both safety 
and efficacy considerations : 
ISO-CC-005 study data demonstrate s no dose -related increase in toxicity when 28 patients were 
dosed with 120  mg/m2 administered with two  separate injections of 60  mg/m2 each.  
PK and met abolism data from the ISO -CC-002 study  suggest attaining a high C max on two occasions 
achieved with the two  injections of 60  mg/m2 may move more arfolitixorin into the cells. In the 
ISO-CC-002 study,  a bolus dose of 60  mg/m2 arfolitixorin provides a pronounced transient increase of 
the [6R] -5,10 -MTHF levels in plasma but disappears wit hin 30  min.  
Furthermore, 5 -FU given as a bolus is known to be rapidly (in 10 to 20  minutes) converted into 
5-FdUMP, which binds highly efficie ntly to the TS enzyme in tumors  under the formation of a binary 
complex . The binary complex  can be further strengthened  by supplying arfolitixorin at the early 
stage after 5 -FU administration  [18]. For this reason , the high transient plasma level of 
[6R]-5,10-MTHF should co -exist with the high concentration of 5 -FdUMP in the tumor . An overall 
optimal treatment should therefore  be obtained by dividing the 120  mg/m2 dose of arfolitixorin into 
two bolus doses, and to achieve a high [6R] -5,10 -MTHF intracellular concentrations over a longer 
period of time the bolus doses should be separated by 30-60 minutes.  
LV 400 mg/ m2 IV infusion has been chosen as the comparator as this is the agent recommended in 
advanced CRC  treatment guidelines [4].    
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 29 Arfolitixorin  or LV will be administered in combination with 5 -FU, oxaliplatin, and bevacizumab.  This 
is standard first -line adjuvant therapy according to current ESMO  and NCCN guidance. All patients in 
this study will receive bevacizumab as it appears to improve PFS when used in combination with 5 -
FU/LV/oxaliplatin [4, 27]. The doses of 5 -FU, oxaliplatin, and bevacizumab specified in this protocol 
are those commonly used in clinical practice and according to their labels.  
4.4 END OF S TUDY DEFINITION  
A patient  is considered to have completed the study if he or she has completed all phases of the study 
including the last scheduled procedure shown in the S chedule of Activities (SoA), Section  1.3, i.e. the 
last contact  (phone, hospital records or other means found suitable)  to collect the death date. 
The final analysis of ORR and  PFS will be performed when at least 235 PFS events have been observed.  
If the sample size is increased to 660 patients, the final analysis of  ORR and  PFS will be performed 
when approximately 450 PFS events have been observed. All study patients will be followed for OS  a 
until 60%  of OS events are achieved  for the study population , i.e. 294 OS events in case the sample 
size is not increased, and 396 OS events in case the sample size is increased to 660 patients . 
At the time of final analysis of ORR and PFS, patients still on IMP treatment will continue IMP 
treatment until locally assessed progressive disease or discontinuation of IMP for other reasons. After completed End of Treatment visit these patients have reached the End of Study definition and will thereafter move into survival follow -up until 60%  of OS events are achieved  for the study population.  
Patient s already in follow -up phase at the time of final analysis of ORR and PFS have reached the End 
of Study definition and will move into survival follow -up until 60%  of OS events are achieved  for the 
study population.  
 
5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
For randomization in the study, patients must fulfill all of the following criteria:  
1. Colorectal adenocarcinoma verified by biopsy.  
2. Availability of biopsy material, from the primary tumor  or metastasis, allowing for analysis of 
tumor  gene expression.  
3. Non -resectable metastatic CRC planned for first line therapy with 5 -FU, Leucovorin, 
oxaliplatin, and bevacizumab.   
4. Evaluable disease with at least one measurable lesion of metastatic disease ( â‰¥10 mm in 
longest diameter on axial image on CT -scan or alternatively MRI with <5 mm reconstruction 
interval) or lymph node ( â‰¥15 mm in shortest axis when assessed by CT) withi n 28 days of 
randomization . 
5. Life ex pectancy of more than 4 months.  
6. ECOG performance status 0 or 1.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 30 7. Hemoglobin (Hb) > 80 g/L, Absolute neutrophil count (ANC) > 1.5x109/L. Thrombocytes > 
100x109/L.  
8. Creatinine clearance > 50 mL/min, Total bilirubin < 1.5 x ULN,  
AST and ALT < 3 x ULN (and < 5 x ULN in case of liver metastases).  
9. Male or female â‰¥18 years of age.  
10. Female patients  of childbearing potential must have a negative urine pregnancy test and use 
adequate contraceptive measures1. Male patients must use adequate contraceptive 
measure s2. 
11. Voluntarily signed  informed consent before performance of any study related procedure not 
part of normal medical care, with the understanding that consent may be withdrawn by the 
patient  at any time without prejudice to future medical care.  
1 Female patients must be post -menopausal for more than one year or must provide a negative pregnancy test and use an efficient 
method of contraception (i.e., a method with less than 1% failure rate [e.g., sterilization, hormone implants, hormone injections, some 
intrauterine devic es, or vasectomized partner]) during the study and for 1 month (or more if requested by non -IMP labels)  after the end of 
the study (last dose of IMP).  
2 Unless the partner of a male patient is post -menopausal or using an efficient method of contraception a s described above, m ale patients 
must agree to use condoms during the study treatment and for 1 month after the end of the study treatment . 
5.2 EXCLUSION CRITERIA  
Patients meeting one or more of the following criteria are ineligible to participate in the study :  
1. Malignant tumors  other than colorectal adenocarcinomas (current or within the previous five 
years), with the exception for curatively treated non -melanoma skin cancer or in situ 
carcinoma of the cervix.  
2. Less than 6 months between randomization and completion of the last anti -cancer 
treatment (chemotherapy/ radiotherapy/immunotherapy, etc.). (NB: Rectal cancer 
treatment shorter than 8 weeks of chemo/radiation therapy is allowed.)  
3. Confirmation of progressive disease  within  6 months after completion  of prior adjuvant anti -
cancer treatment.  
4. Indication for any mCRC surgery or anti- cancer treatment other than study treatment.  
5. Prior treatment with arfolitixorin . 
6. Indication for treatment with a 5 -FU analogue, or 5 -FU for a condition other than mCRC.  
7. Known DPD deficiency.  
8. Known or suspected  central nervous system metastases.  
9. Unresolved bowel obstruction, uncontrolled Crohnâ€™s disease, or ulcerative colitis.  
10. History of cardiac disease with a New York Heart Association Class II or greater, cong estive 
heart failure, myocardial infarction or unstable angina at any time during the 6 months prior 
to randomization , or serious arrhythmias requiring medication for treatment.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 31 11. Current CTCAE â‰¥ grade 3  diarrhea. 
12. Current chronic infection or uncontrolled serious illness causing immunodeficiency.  
13. Known or suspected hypersensitivity or intolerance to arfolitixorin , LV, 5 -FU, oxaliplatin, or 
bevacizumab.  
14. Breastfeeding patients.  
15. Patient who received investigational drugs in other clinical trials within 28 days, or 5 half- lives 
of the investigational drug, prior to randomization . 
16. Patient with serious medical or psychiatric illness likely to interfere with participation in this 
clinical study.  
17. Ongoing drug or alcohol abuse , as deemed by the I nvestigator. 
18. Any condition that, in the opinion of the Investigator , could compromise the patient 's safety 
or adherence to the study protocol.  
19. Involvement, or related to people involved in the planning or conduct of the study (applies to both Isofol Medica l staff and staff at the study site) . 
20. Surgery (excluding previous diagnostic biopsy) in the 28 -day period before randomization  
 
5.3 LIFESTYLE CONSIDERATIONS  
Not applicable  
5.4 SCREEN FAILURES  
Screening failures are patients  who consent to participate in the clinical trial but are not subsequently 
assigned to the study intervention or entered in the study due to a failure to meet inclusion/exclusion criteria.  These patients should have the reason for study withdrawal recorded  as â€˜Eligibility Criteria 
Not Fulfilledâ€™. Screening failure patients will not be allowed to be rescreened into the study.  
If a patient does not meet all the eligibility criteria but is randomized  in error, or incorrectly started on 
treatment, the Investiga tor should inform the Sponsor  immediately, before a decision is made to 
continue or discontinue the patient from treatment.  
All AEs that occur after the consent form is signed and before treatment allocation/randomization 
must be reported by the Investigator if the  AE cause s the patient to be excluded from the study, or 
are the result of a protocol -specified intervention.    
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
Approximatively 80 -100 sites  across Europe , Canada, the US , Australia and Japan  will participate in the 
study. The recruitment will be competitive between the study sites. With a n estimated  recruitment 
rate of 0. 36 patients per site and month, 440 patients should be recruited in  approximately  19 months  
including 6 months  ramp up period until all sites are activated . The patients will be recruited from the 
sites  ordinary pool of patients. No study site should include more than 10 % of the total number of 
patients in the study (i.e. not exceeding 44 patients, or 66 patients  if the sample size is increased ). 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 32 The recruitment will continue during the interim analysis . Depending on the conditional powers, the 
trial will either continue as planned, or the sample size of the trial will be increased for a total of 660 
randomized pa tients.  
 
Initially, approximately 440 were planned to be randomized. However, Japanese authorities 
requested that approximately 12.7% of the total study population are enrolled from Japan. For this reason, additional patients from Japan were randomized. In the end a total of 490 patients were  
randomized. This decision to randomize extra Japanese patients was made  before the interim 
analysis . The decision to include the Japanese patients in the ITT population (see Section 9.2.2) for 
the primary efficacy analysis was made  after the interim analysis.  
 Study sites should keep  up to date contact information  for all study patients  in their records to 
ensure patient retention throughout  the study, including the survival follow up phase.  
 
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  S TUDY INTERVENTION  DESCRIPTION  
Eligible and consenting patients wi ll be randomized  1:1 to one of two treatment groups (A and B) and 
administered one of the following treatment regimens starting  within 3 days of randomization. 
Following treatment cycles should be started 14 (+ 7) days after the previous administration. 
â€¢ Group A  â€œExperimental â€:  ARFOX  (Arfolitixorin + 5-FU + Oxaliplatin ) + Bevacizumab  
â€¢ Group B  â€œComparatorâ€ :     mFOLFOX -6 (Leucovorin  + 5-FU + Oxaliplatin) + Bevacizumab  
6.1.2  D OSING AND ADMINISTRATION  
Group A ( ARFOX + bevacizumab): 
â€¢ Bevacizumab 5 mg/kg, IV infusion in accordance with the label   
â†“ followed by  
â€¢ Oxaliplatin 85  mg/m2 IV infusion in accordance with the label   
  â†“ followed by  
â€¢ 5-FU 400 mg/m2 IV bolus (2â€“ 4 minutes ) 
  â†“ followed by (30 minutes (Â± 5 minutes) after 5 -FU bolus)  
â€¢ Arfolitixorin  60 mg/m2 rapid IV bolus ( less than 3 minutes ) 
  â†“ followed by  
â€¢ 5-FU 2400 mg/m2 continuous IV infusion over 46 hours  
â†“ followed by (30 -60 minutes after the first arfolitixorin bolus ) 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 33 â€¢ Arfolitixorin  60 mg/m2 rapid IV bolus ( less than 3 minutes ) 
 
Group B (modified FOLFOX -6 + bevacizumab):  
â€¢ Bevacizumab 5 mg /kg, IV infusion in accordance with the label   
â†“ followed by  
â€¢ Oxaliplatin 85  mg/m2 IV infusion in accordance with the label   
â†“ followed by * 
â€¢ LV 400  mg/m2 IV infusion  
  â†“ followed by  
â€¢ 5-FU 400 mg/m2 IV bolus ( 2â€“4 minutes ) 
  â†“ followed by  
â€¢ 5-FU 2400 mg/m2 continuous IV infusion over 46 hours  
*Oxaliplatin and LV may be administered at the same time through two different injection ports. NB: 
Oxaliplatin and LV must not be mixed.  
The doses of arfolitixorin  and LV should not be adjusted.  
5-Fluorouracil and LV  should be administered separately to avoid the formation of a pr ecipitate.  
Following a treatment -related adverse event the doses of 5 -FU, oxaliplatin, and bevacizumab may  be 
adjusted or delayed in accordance with the label  and section  6.3.4 in the protocol . Oxaliplatin cannot 
be substituted but caution should be taken regarding toxicity and in case of toxicity, dose modifications (decrease in infusion rate and/or dose reductions ) according to label should be 
performed  [4, 28] . 
For patients with platinum hypersensitivity, pre -medication with IV dexamethasone, chlorphenamine, 
and ranitidine can be given at the Investigatorâ€™s discretion.  
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.1  A CQUISITION  AND ACCOUNTABILITY  
The IMP (arfolitixorin  and LV) will be sent from Creapharm , with depots  in France  and in the US , direct 
to the study sites. All shipments of IMP to site will be managed through an Interactive Web Response 
Syste m (IWRS).  
At all times, the number of supplied, used and remaining treatment doses should match. The 
Investigator  (or designee) will be responsible for IMP accountability, reconciliation, and record 
maintenance. In accordance with all applicable regulatory requirements, the Investigator  (or 
design ee) must maintain the following inventory records:  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 34 â€¢ Receipt of IMP  boxes at the study site;  
â€¢ IMP administered to eac h patient (including vial numbers);  
â€¢ Inventory of IMP at study site;  
â€¢ Log of any discarded/ unused/expired IMP; 
â€¢ Monitoring of the storage conditions.  
These records will be monitored and verified by the local monitor regularly, as part of the routine 
monitoring procedure.   
Any unused or expired IMP  should be destroyed at site if possible only after Sponsor approval. If 
returned to the supplier locally approved safety procedures and documentation  should be used . 
6.2.2  F ORMUL ATION, APPEARANCE, PACKAGING, AND LABELL ING  
6.2.2.1  STUDY DRUG: ARFOLITIXORIN  
The active pharmaceutical ingredient (API) of arfolitixorin  is the hemisulfate salt of [6R]5,10 -
methylene- tetrahydrofolic  acid ([6R] -MTH F-HS). The API is manufactured in accordance with Good 
Manufacturing Practice (GMP) by Merck & Cie  (Schaffhausen, Switzerland) . 
The drug product, a rfolitixorin  powder for injection 100 mg, is a lyophilized white to light yellowish or 
light  beige powder (100 mg arfolitixorin  per vial, calculated as free acid) for administration after  
reconstitution with 10 mL of water for injection. The drug product i s manufactured in accordance with 
GMP by Recipharm (Wasserburg, Germany)  
Table 2: Components of arfolitixorin  
Component  Amount/vial  Function  
Sodium hydroxide  0.031 g For pH adjustment  
Trisodium citrate dihydrate  0.2 g  Buffer (to guarantee a defined stable pH  after 
reconstitution in water)  
Arfolitixorin  0.1 g  Active Ingredient  
 
1) The listed amount of Sodium hydroxide (2 N in WFI) can vary slightly since the final amounts are dependent on 
the pH -adjustment. During the lyophilization process, water is removed.  
Reconstitution is performed prior to administration (see section 6.2.4.1). The resulting solution for 
injection is isotonic and  has a pH of 8.5. The final API conce ntration is 10 mg/mL calculated as the free 
acid.  
The primary packaging is  10 mL type 1 glass vials with lyophilization stopper (20 mm,  siliconized, 
Helvoet FM157/1, light grey) and flip -off cap (20 mm with white synthetic disc) . 
Arfolitixorin  vials  are labeled  by Creapharm  in accordance with GMP and local regulatory guidelines.  
The labels fulfil GMP Annex 13 requirements for labelling. Label text will be translated into local 
language .  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 35 6.2.2.2  C OMPARATOR DRUG : LEUCOVORIN  
 
The comparator, Leucovorin ( calcium folinate ) 10 mg/m L is a commercialized specialty which will be 
provided to the sites by Creapharm.  
Each vial of 20 m L solution contains 10 mg/m L of folinic acid provided as calcium folinate.  
List of excipients  
â€¢ Sodium Chloride  
â€¢ Water for Injection  
Calcium folinate  vials  are labeled  by Creapharm  in accordance with GMP and local regulatory 
guidelines. The labels fulfil GMP Annex 13 requirements for labelling.  Label text is  translated into local 
language.  
6.2.3  P RODUCT STORAGE AND STABILITY  
6.2.3.1  STUDY DRUG: ARFOLITIXORIN  
Stability tests according to ICH (International Conference on Harmonization ) guidelines are ongoing. 
The study  drug product should be  stored at 2 â€“ 8Â°C. Reconstituted powder (for details see  6.2.4.1 ) can 
be handled at room temperature and should be a dministrat ed within 2 hours . 
6.2.3.2  C OMPARATOR DRUG : LEUCOVORIN  
The comparator is commercialized Leucovorin ( calcium folinate ) and should be stored at 2 â€“ 8Â°C, 
protected from light . 
6.2.4  P REPARATION  
 
The study drug is allocated using the IWRS. The doses are based on the patientâ€™s body surface area and is calculated using the DuBois formula:  
BSA = 0.007184 x Height
0.725 x Weight0.425 
6.2.4.1  S TUDY DRUG: ARFOLITIXORIN  
 
1. Arfolitixorin solution for injection should be prepared by trained personnel, for example at 
the hospital pharmacy or by a registered nurse.  
 
2. Use aseptic technique.   
3. Reconstitute each vial (100 mg) with 10 mL water for injection and note the time point for reconstitution. Gently swirl each vial until the powder is completely dissolved. The solution 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 36 should be  clear and range in colour from colourless to yellow. The solution contains 10 
mg/mL arfolitixorin . 
 
4. Inspect the solution visually for particles. If particles are present, discard the solution.  
 
5. The solution can be kept in the vial, alternatively, directly after the visual inspection 
transferred to a syringe according to standard procedure.  
 
6. Storage conditions for th e solution:  
 
a. If the solution is stored at room temperature it must be administered within 2 hours from the time of reconstitution. Document the expiry time.  
 
b. If the solution is stored in the refrigerator (2 -8 Â°C) it must be administered within 6 
hours from  the time of reconstitution. Document the expiry time.  
 
c. If the solution is not administered before it expires, it must be discarded.  
6.2.4.2  C
OMPARATOR DRUG : LEUCOVORIN  (LV)  
The preparation should be performed according to the product preparation instructions .  
For intravenous infusion, LV may be diluted with 0.9% sodium chloride solution or 5% glucose solution 
before use. Refer also to section 6.3. 
5-Fluorouracil and LV  should be administered separately to avoid the formation of a precipitate.  
As the LV used in this study is Bendafolin which contains the excipient trometamol, LV may no t be 
mixed with oxaliplatin during the administration of the study drugs.  
6.3 OTHER MEDICATIONS  
6.3.1  5-FU 
5-FU is formulated as injection solution.  
5-FU  Dosing:  
Per label, 5-FU will be administered as a 400 mg/m2 IV bolus (2 â€“4 minutes)  on Day 1 followed by  
continuous  2400 mg/m2 IV infusion over 46 hours  in each treatment cycle. The treatment will be 
repeated every two weeks  until PD or premature discontinuation of IMP . 
An administered 5 -FU IV bolus dose should not surpass the maximum recommended daily dose o f 
1000 mg, regardless of the body surface area.  
6.3.2  O XALIPLATIN  
Oxaliplatin is formulated as a concentrated infusion solution.  
Oxaliplatin Dosing:  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 37 Per label, Oxaliplatin will be administered as 85 mg/m2 IV infusion over  15 â€“ 120 minutes on Day 1 in 
each treatment cycle and repeated every two  week s until PD or premature discontinuation of IMP. 
Caution will be taken regarding toxicity and in case of toxicity, dose modifications (decrease in infusion 
rate and/or dose reductions) acco rding to label should be performed.  
6.3.3  B EVACIZUMAB  
Bevacizumab is formulated as a concentrated infusion solution.  
US licensed b evacizumab biosimilars are allowed for treatment . A biosimilar is a biological product 
that is highly similar to and has no clinically meaningful differences from an existing biologic therapy. 
Several biosimilars  are available on the U.S. market, including bevacizumab- awwb and -bvzr that have 
been FDA app roved for the treatment of mCRC . The biosimilars are however not interchangeable  and 
no patient  may therefore change between bevacizumab and any biosimilar  treatment  or between 
different biosimilars during the course of the  study.  
Bevacizumab  D osing:  
Per label, Bevacizumab administered as an intravenous infusion as 5 mg/kg of body weight given once 
every 2 weeks. It will be administered on Day 1 of every 2 -week cycle  and repeated every two weeks 
until PD, premature discontinuation of IMP  or un acceptable toxicity . The initial dose should be 
delivered over 90  minutes as an intravenous infusion. If the first infusion is well tolerated, the second 
infusion may be administered over 60 minutes. If the 60 -minute infusion is well tolerated, all 
subsequ ent infusions may be administered over 30 minutes. It should not be administered as an 
intravenous push or bolus.   
6.3.4  D OSE ADJUSTEMENTS  
On the planned day of treatment, chemotherapy may be administered only if:  
â€¢ ANC is â‰¥ 1.0 Ã— 103/ÂµL (1.0 Ã— 109/L)â€  
â€¢ Platelet count is â‰¥ 75 Ã— 103/ÂµL (75 Ã— 109/L) 
â€¢ Chemotherapy -related gastrointestinal toxicity is â‰¤ Grade 1  
â€  In situations where ANC is < 1.5 Ã— 103/ÂµL (1.5 Ã— 109/L) but â‰¥ 1.0 Ã— 103/ÂµL (1.0 Ã— 109/L) and institutional 
guidelines (or I nvestigatorâ€™s discretion) recommend not administering chemotherapy, then 
chemotherapy may be delayed . 
General dose -modification considerations are as follows:  
â€¢ All study patients should receive standard approaches to dosing and dose modification for adverse reactions that are consis tent with approved product labeling for the individual drugs 
within the combination chemotherapy regimen.   
â€¢ If 5-FU administration is delayed, oxaliplatin, bevacizumab , arfolitixorin  or LV must also be 
postponed  
â€¢ If 5-FU treatment is discontinued  the patien t will be withdraw n from the study  treatment and 
followed for OS . 
â€¢ 5-FU dose reductions are allowed in case of toxicity , but the 5-FU bolus may not be removed  
if the 5 -FU treatment continues. Instead both the 5- FU bolus and 5 -FU infusion dose should 
be reduced according to the rates described in the 5 -FU summary of product characteristics 
[34]. 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 38 â€¢ If oxaliplatin  or bevacizumab  administration is delayed or discontinued, 5 -FU/arfolitixorin  or 
LV may be continued.  
â€¢ Dose reductions for arfolitixorin  or LV  are not allowed ; however, arfolitixorin  or LV will always 
be withheld when 5 -FU is withheld.  
All dose modifications and treatment  discontinuations will be captured in the eCRF.  
 
 
6.4 MEASURES TO MINIMIZE BIAS: RANDOMIZATION  AND BLINDING  
6.4.1  RANDOMIZATION  
Patients will be randomized in a 1:1 ratio  to either the experimental  arm ( arfolitixorin ) or the 
comparator arm (Leucovorin) , following the completion of all screening  assessments and after 
confirmation of their eligibility, using a stratified permuted block randomization. Randomization will 
be stratified  for the following baseline factors :  
â€¢ Geographical region (Europe versus  North America  versus  Australia versus  Japan ) 
â€¢ Primary tumor location ( left colon  versus  right colon  versus  rectal cancer) 
â€¢ Previous neo-adjuvant/ adjuvant CRC treatment  (yes versus  no) 
Randomization will be performed via an interactive web response system (IWRS). The system enables 
time and date stamped entries that in turn allow real time compliance  monitoring.  
The system is compliant with the FDA 21 CFR Part 11 standards ensuring the systemâ€™s secured  access 
and integrity of data collected.  In this respect, any person involved with the IWRS will be  identified by 
a personal username and  will need a secret code to access the system.  
6.4.2  B LINDING  
Patient and Investigator blinding of the study treatment is not possible as there is a difference in the 
color  of the injection fluids and the method of administration. T o minimize  any bias arising either from 
the inability to blind patients and Investigator s or from potential inconsistencies in local tumor  
resp onse assessments across study sites, analyses of the tumor  response endpoints will be based on 
BICR, i.e. blinded, retrospective, centrally -adjudicated assessment of CT -scans/MRIs according to a 
pre-specified Image Review Charter.  
6.5 STUDY INTERVENTION  COMPLI ANCE  
Date and procedures of each study visit will be entered  in the electronic case report form (eCRF) to 
document patient compliance  to the study schedule as well as to the study procedures (for instance 
complies with the prohibited concomitant therapies ). 
In addition, during monitoring visit done at the Investigatorâ€™s site, the monitor  will check that:  
â€¢ All IMPs  and procedures  for the trial are to be used exclusively within the limits defined by the  
protocol;  
â€¢ Inventory records of study products are in order and that there are sufficient supplies ; 
â€¢ The expiry dates are not likely to  be, or have not been, exceeded;  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 39 â€¢ The storage conditions for study products are adequate;  
â€¢ Procedures and records of returned and/or unused study products  are complete . 
 
6.6 CONCOMITANT THERAPY  
6.6.1  PROHIBITED THERAPIES  
The following treatments are not permitted:  
â€¢ nucleoside analogues ( e.g., sorivud ine) or known DPD inhibitors ( e.g., brivudin)  
â€¢ additional anti- cancer treatment ( e.g., chemotherapy, biologics, etc.) except  what is described 
in Section  6.3 
â€¢ experim ental medications other than arfolitixorin  
â€¢ therapeutic radiation therapy. Palliative radiation can be approved by sponsor on a case by 
case basis.  
If any of the foregoing treatments are considered essential during the study the patient is to 
discontinue IMP  as per section 7.1 .  
6.6.2  A UTHORIZED  MEDICATION  
Throughout the study, patients will receive medication required for their health condition  at the 
discretion of the I nvestigator or treating physician, if not included in the list of prohibited medication  
(section 6.6.1) . All concomitant treatment administered at any time, from t he screening visit until the 
End of Treatment visit , will be recorded in the eCRF on a medication form (including the generic  name 
of the medication, the medical indication/AE, the daily dose, the  route of administration and  the start 
and end dates ). After IMP discontinuation, further anti-cancer therapies will be recorded in the eCRF , 
until death or end of study . After the last administration of study treatment , the patients will be 
treated  according to local clinical practice . 
Also,  the use of v itamins and dietary supplements will be recorded in the eCRF.  
6.6.3  RE SCUE MEDICINE  
Not applicable  
7 IMP  DISCONTINUATION AND PA TIENT  DISCONTINUATION  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
The IMP treatment can be discontinued based on the decision of the patient, the Investigator , or the 
Sponsor , as follows:  
â€¢ Patients may voluntarily discontinue the IMP at any time without providing a reason and 
without any prejudice t o future treatment.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 40 â€¢ The Investigator  may, at their discretion, discontinue the IMP at any time if deemed to be in 
the best interest of the patient (including AEs, complete  response, or symptomatic 
deterioration ), or due to incorrect randomization, or preg nancy.   
â€¢ The Sponsor  may also instruct  the Investigator to discontinue treatment with IMP in the event 
of severe non -compliance with the protocol ( e.g., refusal to adhere to the treatment schedule  
or other protocol related assessments ), or a protocol deviation that could affect the safety or 
well- being of the patient , or if new safety information showing unfavorable data becomes 
available .   
Patients prematurely discontinuing the IMP are to be treated according to local routine. Patients will 
be asked to complete an end of treatment visit within 30 days of last dose of IMP and before start of 
new anti -cancer treatment. 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE S TUDY  
Patients are free to with draw from the study at any time, without necessarily providing a reason and 
without prejudice to further treatment.  
A patient who withdraws consent will always be asked the reason(s) for the withdrawal and the 
presence of any AEs. Patients will also be asked the following:  
â€¢ To complete an E nd of T reatment visit . 
â€¢ To permit the Investigator  to follow -up (including by telephone) and provide data to the 
Sponsor  regarding OS  and anti -cancer therapy . 
â€¢ If the patient does not have PD at the time of withdrawal, to permit the Investigator to 
continue to provide data to the Sponsor  regarding PD (either or both the Investigator â€™s 
determination of PD or any future CT -scans/MRIs) and anti -cancer therapy . 
Every effort will be made to minimize the number of patients withdrawing from the trial or lost to 
follow -up. A patient may withdraw from study treatment, however still continue to be followed until 
PD and/or death. Only patients who explicitly withdraw their consent or who are completely lost to 
follow -up will be considered â€œdropoutsâ€. Data for these patients will be kept in the data base, unless 
the patient request that all his/her data to be deleted from the data base.  
Randomized  patients  who have received IMP  and withdraw s from participation in the study will not 
be replaced . 
7.3 LOST TO F OLLOW-UP 
To minimize lost to follow -up in the study, each site should ensure contact details  (including relative)  
are updated when the patient is entering the study. A study patient  will be considered lost to follow -
up if he or she fails  to return for scheduled visits and  is unable to be contacted by the study site  staff 
for six months after last study visit . Should the participant continue to be unreachable, he or she will 
be considered to have withdrawn from the study with a primary reason of lost to follow -up. 
Before declaring a patient to be â€œLost to follow -upâ€,  reasonable effort should be spent  in followin g 
actions:  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 41 â€¢ The site will attempt to contact the participant and reschedule the missed visit and counsel 
the participant on the importance of maintaining the assigned visit schedule and ascertain if 
the participant wishes to and/or should continue in the st udy.  
â€¢ Before a participant is deemed lost to follow -up, the Investigator or designee will make every 
effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, a certified letter to the participantâ€™s last known mailing address or local equivalent methods). These contact attempts will be documented in the participantâ€™s medical record or 
study file.  
8 STUDY ASSESSMENTS AND PROCEDURES  
 
8.1 EFFICACY ASSESSMENTS  
8.1.1  CT SCAN / MRI  
CT-scans or MRIs will be performed of the thorax, abdomen, and pelvis at screening and every 8 weeks 
after randomization  until centrally confirmed PD . A radiologist at each study site/hospital (preferably 
the same radiologist for all patients at that hospital) is to evaluate  each scan for target lesions. The 
following information is to be collected:  
â€¢ Patient ID  
â€¢ Date of procedure  
â€¢ Type of procedure  
â€¢ Progressive disease (Yes/No)  
It is preferred that the scans for a patient is taken with the same technique (CT or MRI) throughout 
the study. On occasions  where it is not possible , for whatever reason, to use the same technique as 
for the screening scan the other technique should be us ed. The technique used for each scan will be 
documented in the eCRF.  
To minimize bias and have an objective  assessment of the tumor response, a central imaging vendor 
(Banook Group) will perform independent and blinded response evaluations retrospectively.  
The central reading process will be  done from screening until centrally confirmed PD by two different 
Cent ral Readers (double review with adjudication). All the images will be sent  to the Central Readers 
in a continues  chronological sequence  as outlined in the Site Procedure Manual . In order to remove 
the bias of interpolation and ensure the reader concentrate s on the latest time- point images and has 
no idea that there are more to follow, each time -point images will be displayed, scored and locked in 
the database before the assessment of the following time point.  
The methodology applied at baseline regarding the identification of the target and non -target lesions 
is based on a common lesions selection process and an identical usage of those selected lesions by both Central Readers.  
The rationale for this lesion selection process at baseline is based on the fact  that readers can 
potentially identify different target and non -target lesions that each considers representative of the 
patient 's overall extent of disease. There is also the potential for the Central Readers to identify the 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 42 same lesions but classify them  differently between target and non -target lesions. Discordance in lesion 
selection can reach 40% or even more. In addition, since lesions do not respond or progress at the 
same rate, differences between readers with regard to response or progression of le sions can be 
observed in the subsequent time -points.  
To minimize such important risk of discordance, the following process for the initial CT -scan or MRI 
will be applied . 
One of the two primary Central Readers is randomly selected to perform lesions selection on initial 
images : 
â€¢ Determines the number of target lesions and non -target lesions based on RECIST 1.1,  
â€¢ Communicates the target and not target lesions identification to the second primary Central Reader, via the central imaging vendor  to preserve the independence of the two Central 
Readers.  
â€¢ Tracks lesions locations and labelling for up to 5 (2 per organ) target lesions and 10 non -target 
lesions on the subsequent time points.  
 After having defined the type of targets and others lesions to be selected, the two primary Central 
Readers will carry out a separate and blinded measurement of the target lesions at Baseline:  
â€¢ If there is an agreement between Central Readers (Î” âˆ‘ <20% and Î” <15% for each lesion), 
Central Reader will keep his own âˆ‘ for  the next time points,  
In case of discrepancies between Central Readers (Î” âˆ‘ >20% or Î” >15% for any lesion), the Central 
Chair/adjudicator) will adjudicate the result of the two previous Central Readers and will provide the 
reference values for the baseline (for each target lesion). This value will be considered as reference by both Central Readers for the next time point analyses.
 
8.1.1.1  INITIAL  CT-SCAN OR MRI  
 Tumor imaging at screening must be performed within 28 days prior to the date of randomization. Scans performed as part of routine clinical management are acceptable for use as screening tumor imaging if they are of diagnostic quality and performed within 28 days prior to the date of randomization and fulfill the requirements stipulated  by the central imaging vendor.  
 Overall review of the TAP  (thorax, abdomen, pelvis) CT -scan  or MRI for response assessment will only 
be performed on patient s delivering an evaluable baseline time point and at least one evaluable 
follow -up time point.  
 
8.1.1.2  S
UBSEQUENT TIME POINTS  
The two Central Readers will carry out a continuous reading at each complete patient in a blind way 
one versus the other. Initial images are intended to act as a lesion reference map for lesion 
assessments made during subsequent time point review.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 43 â€¢ The Central Readers perform lesion(s) measurements at each subsequent time point  as 
described in the Central Review Charter ,  
â€¢ The Central Readers assess the outcome of non -target lesions,  
â€¢ The Central Readers determine, if any, the number and location of new lesion (s), 
â€¢ The Central Readers provide an overall response assessment.   
8.1.1.3  RE CIST CRITERIA  
Tumor response will be evaluated according to the following definitions, as per RECIST 1.1 criteria. 
(NB: Investigator s are to rely on the locally -performed assessment for  treatment  guidance) . The 
centrally -performed assessment will be the basis for evaluation of the study endpoints : 
Complete Response (CR)  Disappearance of all target lesions.  Any pathological lymph 
nodes (whether target or non -target) must have reduction 
in short axis to <10 mm. 
 
Partial Response (PR)  At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters.  
Progressive Disease (PD)  At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 
(Note: the appearance of one or more new lesions is also 
considered progression).  
 
Stable Disease (SD)  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum diameters while on study.
 
8.1.2  P HARMACO KINETICS  
The plasma concentration  of [6R] -MTHF, methyl -THF, THF will be determined in a pproximately 20 
patients  per treatment group . The sample size is not based on pop -PK modelling, but on feasibility as 
the sampling requires access to laboratory facilities at the site. Blood samples for determination of folate PK characteristics will be collected from those patients randomized  at clinical sites qualified to 
ensure correct handling of samples in accordance wit h study -specific instructions.  
PK sampling procedures  
Plasma sampling will occur during Cycle 1 (Week 1) and Cycle 2 (Week 3) . 
PK sampling for the experimental arm  (Timings of PK samplings are approximate and actual sampling 
times will be captured in the PK sample log) : 
1. Directly prior to the first arfolitixorin administration  
2. 10 minutes after the first arfolitixorin administration   
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 44 3. 1 hour after the first arfolitixorin administration  (NB: This sample will be taken after the 
second arfolitixorin dose)   
4. Directly prior to the second  arfolitixorin administration  
5. 10 minutes after the second arfolitixorin administration   
6. 1 hour after the second arfolitixorin administration  
PK sampling schedule for the comparator arm  (Timings of PK samplings are approximate and actual 
sampling times will be captured in the PK sample log) : 
1. Directly prior to the initiation of the Leucovorin infusion   
2. 10 minutes after completion of the Leucovorin infusion  
3. 10 min after the 5 -FU Bolus 
4. 1 h after initiation of 5 -FU infusion  
In total 12/8 PK samples will be collected from each patient in the arfolitixorin/Leucovorin group 
participating in the PK part of the study yielding approximately 60/40 mL blood collected for this 
purpose . 
The study  site should strive to take the blood samples as close to the suggested time-points as 
possible.  The exact sampling time will be recorded in the eCRF and will be used for the PK calculations.  
Plasma samples will be collected, handled, stored, and sent to Charles River Laboratories, (UK  and 
USA) for analysis as described in study -specific laboratory instructions.  All samples collected for each 
patient will be analyzed  at the same time.  
Bioanalytical method 
A validated  bioanalytical method for the determination of levels of [6R]-MTHF, methyl -THF and THF is 
described in a separate bioanalytical method protocol.  
8.1.2.1  P OPULATION PHARM ACOKINETIC ANALYSIS  
The pharmacokinetics of [6R] -MTHF will be analyzed  using a population PK approach. The specific 
objectives of the analysis are to:  
â€¢ Characterize the single and multiple dose pharmacokinetics, including associated variability, of 
[6R]-MTHF.   
â€¢ Evaluate the impact of potential covariates (body size, age, sex, race, ethnicity and renal function) on the pharmacokinetics of [6R] -MTHF.  
In addition to the concentration data collected in study ISO -CC-007 (see section 8.1.2  for the 
sampling schedule and anticipated number of patients), data  from three Phase I/II studies in patients 
(ISO-MC-091, ISO -CC-002 and ISO -CC-005) and from one Phase  I study in healthy volunteers  (ISO-FF-
001) will be included in the population PK analysis.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 45 The population PK analysis will be performed in a stepwise manner as outlined below.  
1. Exploratory graphical analysis of plasma concentrations versus time data and covariate 
distributions, for identification of potential outliers and to inform the further analysis.  
2. Develop a population PK model for [6R] -MTHF:  
a. Evaluate alternative structural and stochastic models to describe the typical [6R] -
MTHF PK profile.  
b. Investigate and characterize covariates t hat influence the volume of distribution, 
and clearance for [6R] -MTHF.  
c. Evaluate, and if necessary refine, the candidate final model.  
The population PK analysis will be described in a population PK report. The report will contain a thorough description of the data used in the analysis, including any data exclusions and handling of missing data; the key components of the model development, including the base model, covariate analysis and model evaluation; and full description and discussion of the final model.  
8.1.2.2  E
XPOSURE -RESPONSE ANALYSIS  
The aim of the exposure- response analysis is to evaluate the suitability of the dose of 120 mg/m2. 
The individual [6R] -MTHF exposure (AUC average  and C max), as established from the population PK 
analysis described above, will b e used in the exposure- response analysis  (see section  8.1.2 for 
anticipated number of patients ). The following efficacy and safety parameters will be evaluated for a 
correlation with exposure:  
â€¢ ORR  
â€¢ Dose limiting toxicities  
â€¢ Adverse events  
 
In addition  to the exposure -response data collected in this study (ISO-CC-007), data from study ISO -
CC-005 will be included in the exposure -response analysis. The analysis will be described in a 
separate report. The exposure- response report will contain a thorough description of the data used 
in the analysis, including any data exclusions and handling of missing data.  
8.1.3  EC OG PERFORMANCE STATUS   
The ECOG performance status scale will be used to quantify the extent to which the disease affects 
the daily living abilities of the patient on a scale  from 0 to 4 ( Appendix 1). The assessment will be 
performed at screening , baseline (cycle 1),  each assessment visit, at the end of treatment visit, and at 
CT/MRI Follow -up visits until centrally confirmed PD . The scored v alues  will be recorded in the eCRF.  
8.1.4  EQ -5D Q UALITY OF LIFE  
EQ-5D (Appendix 3) patient reported outcome questionnaire will be used to assess the disease effects 
on the patientâ€™s  quality of life . The EQ-5D questionnaire will be completed by the patient prior to any 
study related activity at the visit for first administration of IMP , the assessment visits until PD  and at 
the End of T reatment visit. The EQ -5D questionnaire will be completed  by the patient on paper  and 
then transferred to the e CRF by the study site staff.  
8.1.5  SU RVIVAL STATUS  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 46 Patients discontinuing study treatment and/or with  centrally confirmed PD  will move into the survival 
follow -up phase. Survival status  will be assessed by telephone , ordinary visits , hospital records  or 
other means found suitable  every 12 weeks until death or the end of the study, whichever occurs first.  
Information regarding post -study anti -cancer therapies  will be collected if new treatment is initiate d. 
8.2 SAFETY AND OTHER ASSESSMENTS  
8.2.1  LABORATORY SAFETY ASSESSMENTS   
The laboratory safety samples ( hematology , clinical chemistry, and urinalysis) , including pregnancy 
test,  will be collected according to the protocol Schedule of Activities and in accordance with local 
practice and analyzed  by local laboratories.  
The observed values will be recorded and assessed as â€œnormalâ€ or â€œabnormalâ€ in the eCRF.  Abnormal 
values will be assessed by the Investigator  as â€œclinically significantâ€ or â€œnot clinic ally significantâ€.  
Clinically significant values will be captured as Medical history  or AEs, as applicable.  
The laboratory tests  are to be performed  within 7 days before next treatment and the results must be 
reviewed by the Investigator or qualified designee and found to be acceptable prior to  the 
administration of study treatment. 
All required laboratory tests are specified in  Table 3 . 
Table 3: Laboratory tests  
HEMATOLOGY  CLINICAL CHEMISTRY  URINALYSIS  
Hemoglobin   Sodium  Protein  
Hematocrit  Potassium  Glucose  
WBC  Calcium  Blood  
Neutrophils  Glucose    
Lymphocytes  BUN or urea   
Monocytes  Creatinine   
Eosinophils  AST  
Basophils  ALT   
Platelet count  Alkaline phosphatase    
 Total bilirubin    
 Total protein    
 Albumin    
 LDH   
 gGT  
8.2.2  VITAL SIGNS, ECG  AND  PHYSICAL FINDINGS RELATED TO SAFETY   
Vital signs collected will include resting heart rate (beats per minute), systolic and diastolic blood pressure (mmHg; to be measured after at least five minutes of supine rest), weight (within 7 days prior 
to each stu dy drug administration) , and height (screening only).  
The physical examination is to be performed according to local clinical practice, and include neurological status, skin, and mucous membranes.  
A 12 -lead ECG will be performed at treatment cycles  1 to 4 . Information about the ECG examination 
must be present in the source documentation at the study site.  Single 12 -lead safety ECGs will be 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 47 recorded in supine or in reclining position (should be the same position for all measurements during 
the same day) usi ng the site's ECG machine.  
â€¢ Group A (Arfolitixorin): ECG should be assessed directly prior to each arfolitixorin 
administration, and  10 min (Â± 5 min) after the completion of  each  administration  (i.e. 4 ECG 
per treatment cycle). 
â€¢ Group B (Leucovorin): ECG should be assessed directly prior to Leucovorin infusion, and  10 
min (Â± 5 min) after start of Leucovorin infusion (i.e. 2 ECG per treatment cycle) . 
Safety ECGs will be reviewed and interpreted on -site by the investigator.  Signific ant findings present 
prior to the start of study treatment administration must be recorded in the Medical history  section 
of the eCRF . Clinically significant findings made after the start of study treatment administration, and 
which meet the definition of an AE, must be recorded in the eCRF.  QTc abnormalities should be 
reassessed after 10 minutes to ensure normalization. If a patient develops a change -from -baseline in 
QTcF > 60 ms or a QTcF interval of > 500 ms, ECG should be monitored until normalized, and  the 
patient should be discontinued from  IMP treatment. 
8.2.3  P RO CTCAE  
The PRO CTCAE (Appendix 2) adverse event self -assessment questionnaire will be completed by the 
patient immediately after completion of the EQ -5D questionnaire during the first 4 IMP administration  
visit, during the assessment visits until PD and at the End of Treatment visit. The PRO CTCAE will be 
completed by the patient on paper , and then transferred to the eCRF by the site staff.  The PRO CTCAE 
questionnaire will only be used in countries where there is a validated translation available at the time 
of study submission to IRB/IEC. 
The Investigator must always c onduct an ordinary AE assessment during all study visits independently 
of the information provided by the patient in the PRO CTCAE.  
AEs to be assessed by PRO CTCAE is:  
â€¢ Mucositis  
â€¢ Nausea  
â€¢ Vomiting  
â€¢ Diarrhea  
â€¢ Pain in the abdomen  
â€¢ Neuropathy  
â€¢ Fatigue  
The above AEs are the most frequently reported AEs from the previously conducted and ongoing 
Phase I/II studies with arfolitixorin in combination with 5 -FU, and also including the most commonly 
reported AEs for the anti -cancer treatment  combination used in this protocol  (modified FOLFOX -6 + 
bevacizumab)  [14, 29]. 
8.2.4  P HARMACOGENETICS  
Level of gene expression will be analyzed at a central laboratory  (TATAA Biocenter , Gothenburg, 
Sweden ) to determine drug metabolism - and transportation -related  gene expression levels in all 
patients.  The specifications and logistics for the gene analysis (preparation and shipment of FFPE 
tissue slices  from tumor biopsies to the central laboratory) are described in a separate study -specific  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 48 laboratory instruction  provided to the sites.  The relative gene expression levels  will be analyze d for 
the following genes: ABCC1, ABCC3, ABCC5, CES2, DPYD, ERCC1, FGF7, MTHFD2,  SHMT1 , SHMT2, 
SLC46A1, SLC19A1, SLC24A32, TGFB1, TYMS, ACTB and PPIA . The gene expression analysis  will be 
performed retrospectively.  
8.2.5  RES ECTION/REMOVAL OF TUMOR  LESION (S)  
For patients  assessed by the investigator as eligible for metastasis  and/or primary tumor  resection 
during the IMP treatment phase , treatment with the study regimen may be continued at the 
investigator discretion. The therapy  will be registered in the eCRF including if continued study 
treatment is intended as well as  planned delay until contin ued treatment. The EoT visit will be 
conducted when the IMP treatment has been completed. If the patient discontinues IMP treatment 
in conjunction with the resection, the EoT visit will be conducted within 30 days after last dose of IMP. Patients undergoin g metastasis and/or primary tumor resection  will be followed for disease 
recurrence by central imaging and Overall Survival until death or the end of the study.  
 
8.3 STUDY SCHEDULE  
8.3.1  SCREENING AND ENROLLMENT  
Investigators must keep a record of all patients enrolled  in to the study . 
During the screening period, Investigator s will:  
â€¢ Obtain signed informed consent from the patient before any study sp ecific procedures are 
performed  
â€¢ Assign the patient a unique Patient Study Identifier (ID) 
â€¢ Determine patient eligibility  
â€¢ Record patient demographic data  (date of birth, gender and race)  and gene mutations (BRAF, 
KRAS, NRAS and other) where this information is available in the patientÂ´s medical records.  
â€¢ Record medical history  
â€¢ Record all concomitant therapies  
â€¢ Conduct physical examination  and record vital signs  
â€¢ Assess ECOG status  
â€¢ Record w eight  and height  
â€¢ Collection of blood sample for hematology ( within 7 days before IMP administration ) 
â€¢ Collection of blood sample for clinical chemistry (within 7 days before IMP administration ) 
â€¢ Collection of urine sample  for urinalysis  (within 7 days before IMP administration) 
â€¢ Conduct  pregnancy test for all women of childbearing potential ( within 7 days before IMP 
administration ) 
â€¢ Conduct CT scan / MRI  
â€¢ Ensure availability of tumor tissue biopsy  
If a patient withdraws from participation in the study, then his/her ID code must not be reused.  
Investigators must file Patient Identification Lists of all patients enrolled that include sufficient information to link eCRF data with  clinical records.  This list should be available at the study site  for 
possible future inspections/audits . Sponsor  staff or representatives should only have access to the list  
for monitoring or auditing purposes.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 49 If a CT -scan/MRI was performed before enrolment a new scan is not required, provided that the scan 
occurred no more than 28 days before start of treatment and can be assessed by the central imaging 
vendor . 
Study t reatment should be initiated within  28 days after enrolment . 
8.3.2  B ASELINE (CYCLE 1)  
During the first treatment visit  the following will occur : 
â€¢ Collect PRO EQ -5D (prior to any other study specific activity)  
â€¢ Collect PRO CTCAE  (immediately after EQ -5D) 
â€¢ Assessment of the inclusion/exclusion criteria  
â€¢ Randomization  (should be done within  three days before  study  treatment initiation)  
â€¢ Record adverse event assessment between visits  
â€¢ Record all concomitant therapies  added and/or changed  
â€¢ Conduct physical examination and record vital signs  
â€¢ Record w eight   
â€¢ Conduct ECG  
â€¢ Assess ECOG status  
â€¢ Administer and record study treatments  (i.e. 1st cycle)  
â€¢ Collection of blood sample for PK  (only at pre -selected sites )  
8.3.3  T REATMENT PERIOD  
8.3.3.1  TREATMENT VISITS  
Treatment visits will occur every 14 days  (+7 days)  until PD .  
During all following treatment visits, the following will occur : 
â€¢ Collect PRO CTCAE , treatment visits 2-4 (prior to any other study specific activity)  
â€¢ Record adverse event/toxicity assessment between visits and during IMP administration  
â€¢ Record all concomitant therapies added and/or changed  
â€¢ Record v ital signs  
â€¢ Record w eight  
â€¢ Conduct ECG, treatment visits 2 -4 
â€¢ Collection of blood sample for hematology  (results evaluated prior to IMP administration)  
â€¢ Collection of blood sample for clinical chemi stry (results evaluated prior to IMP 
administration)  
â€¢ Collection of urine sample  for urinalysis  (results evaluated prior to IMP administration)  
â€¢ Administer and record study treatments  
â€¢ Collection of blood sample for PK at cycle 2 (on ly at pre-selected sites )  
At each treatment visit, the collection of blood and urine samples and the record ing of vital signs must 
occur before start of treatment. Following a treatment -related adverse event the doses of 5 -FU, 
oxaliplatin, and bevacizumab can b e adjusted or delayed in accordance with the label  and protocol 
section  6.3.4. Oxaliplatin cannot be substituted but caution should be taken regarding toxicity and in 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 50 case of toxicity, dose modifications (decrease in infusion rate and/or dose reductions) according to 
label should be performed . In case the 5 -FU is delayed the IMP will be delayed.  
8.3.3.2  ASSE SSMENT VISITS (EVERY 8 WEEKS UNTIL PD)  
Assessment visits are to occur every 8 weeks (Â± 7 days ) after the baseline visit (1st IMP administration 
day). During these visits, the following will occur : 
â€¢ Collect PRO EQ- 5D (prior to any other study specific activity)  
â€¢ Collect PRO  CTCAE  (immediately after EQ -5D) 
â€¢ Record adverse event/toxicity assessment between visits  
â€¢ Record all concomitant therapies added and/or changed  
â€¢ Conduct physical examination and record vital signs  
â€¢ Record w eight  
â€¢ Assess ECOG status  
â€¢ Conduct CT scan / MRI  
â€¢ Evaluate disease status  
Assessment visits should continue until PD or premature discontinuation of IMP.  
8.3.4  EN D OF TREATMENT VISIT  (EOT)  
All p atients discontinuing IMP should complete an EOT  visit within 30 days of discontinuation (or as 
soon as possible thereafter) . The EOT  visit should preferably be conducted  before initiation of new 
anti-cancer  therapy. During this visit, the following will occur : 
â€¢ Collect PRO EQ- 5D (prior to any other study specific activity)  
â€¢ Collect PRO  CTCAE  (immediately after EQ -5D) 
â€¢ Record adverse event/ toxicity assessment prior this visit .  
â€¢ Record all concomitant therapies  added and/or changed  
â€¢ Conduct physical examination and record vital signs  
â€¢ Record w eight  
â€¢ Collection of blood sample for hematology  
â€¢ Collection of blood sample for clinical chemistry  
â€¢ Conduct  pregnancy test for all women of childbearing potential  
â€¢ Collection of urine  sample  for urinalysis  
â€¢ Assess ECOG status  
â€¢ Conduct CT scan / MRI (if previous scan is >14 days)  
8.3.5  P OST -TREATMENT VISITS 
At the time of final analysis of ORR and PFS, patients still on IMP treatment will continue IMP treatment until locally assessed progressive disease or discontinuation of IMP for other reasons. After completed End of Treatment visit these patients have reached th e End of Study definition and will 
thereafter move into survival follow -up until 60%  of OS events are achieved  for the study population.  
Patients already in follow -up phase at the time of final analysis of ORR and PFS have reached the End 
of Study definit ion and will move into survival follow -up until 60%  of OS events are achieved  for the 
study population.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 51 8.3.5.1  F OLLOW -UP VISITS UNTIL PROGRESSIVE DISEASE  
Patients who discontinue IMP for reasons other than centrally confirmed  PD will move into the Follow -
up phase and will be continuing to be assessed every  8 weeks. During this visit, the following will occur:  
â€¢ C onduct CT scan / MRI  
â€¢ Assess ECOG status  
â€¢ Post -study anti -cancer therap ies will be collected if new treatment is initiated  
â€¢ Collect SAEs related to study procedures   
â€¢ Collect SAEs considered to be at least possibly related to IMP  
Every effort should be made to collect information regarding disease status until PD, death, or the end 
of the study.  
8.3.5.2  SU RVIVAL FOLLOW -UP 
Patients  discontinuing study treatment and/or with  centrally confirmed PD  will move into the survival 
follow -up phase. Patient survival status will be assessed every 12 weeks until death or the end of the 
study, whichever occurs first.  Patient su rvival data can be collected by phone, visit, medical records, 
contact with relatives etc. Date of death, or the I nvestigators best estimate of the date of death, 
should be entered in the eCRF.  
Information regarding post -study anti -cancer therapies  will be collected if new treatment is initiated.  
8.4 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.4.1  D EFINITION OF ADVERSE EVENTS (AE)  
 
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product an d which does not necessarily have a causal relationship with this 
treatment. An adverse event can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding, for example), symptom or disease temporally associated with the us e 
of a medicinal product, whether or not considered related to the medicinal product . 
Progression of the cancer under study is not considered an adverse event since the development of the cancer will be followed and reported separately.  
 
8.4.2  D
EFINITION OF SERI OUS ADVERSE EVENTS  (SAE)  
A serious adverse event is any AE occurring at any dose that results in any of the following outcomes:  
â€¢ Death  
â€¢ Is life -threatening  
- A life -threatening adverse drug experience is any AE that places the patient , in the 
view of the Investigator , at immediate risk of death from the reaction as it occurred. 
This does not include a reaction that, had it occurred in a more severe form, might have caused death.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 52 â€¢ A persistent or significant disability/incapacity  
â€¢ Inpatient hospitalization or prolongation of existing hospitalization, except that planned 
hospitalization during days in clinic and surgery or hospitalization for the social reasons or t he 
convenience of the patient  or physician shall not be considered an SAE  
â€¢ A congenital anomaly/birth defect  
â€¢ Important medical event  
- Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be serious when, based upon appropriate medical judgment, the event may jeopardize the patient  and require medical or surgical intervention to 
preven t one of the outcomes listed above . 
Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the develop ment of  drug dependency or drug abuse.  
The following events are not considered to be SAE :  
â€¢ progression of the cancer under study since the development of the cancer will be followed and reported separately.  
â€¢ 
hospitalizations for the  routine treatment or monitoring of the studied indication not 
associated with any deterioration in condition.  
â€¢ hospitalizations for the t reatment, which was elective or pre -planned, for a pre -existing 
condition that is unrelated to the indication under trial and did not worsen  
â€¢ hospitalizations for the a dmission to a hospital or other institution for general care, not 
associated with any deterioration in condition  
â€¢ hospitalizations for the t reatment on an emergency, outpatient basis for an event not  
fulfilling any of the definitions of serious given above and not  resulting in hospital admission.  
8.4.3  C LASSIFICATION OF AN ADVERSE E VENT  
8.4.3.1  SEVERITY OF EVENT  
The severity (intensity) of AE in physical signs or symptoms will be graded by the investigator 
according to the NCI -CTCAE  Version 5.0  [30]. For AEs not listed in NCI -CTCAE , the severity of AE  in 
physical signs or symptoms will be classified as follows:  
â€¢ Grade 1: Mild asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
â€¢ Grade 2 : Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living *.   
â€¢ Grade 3 : Severe or medically significant but not immediately life -threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self- care  activities of daily 
living **.  
â€¢ Grade 4 : Life-threatening consequences; urgent intervention in dicated.  
â€¢ Grade 5 : Death related to AE. 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 53 *Instrumental activities of daily living refer to preparing meals, shopping, using the telephone, 
managing money, etc.  
**Self -care  activities of daily living refer to : bathing, dressing and undressing, eating , using the toilet, 
taking medications, and ability to get out of the bed . 
 
 
8.4.3.2  RELATIONSHIP TO STUDY INTERVENTION  
Causality regarding relationship to administration of any of the  medications in the study  treatment 
regimen , including both IMP  (arfolitixorin /Leucovorin) and non -IMP (5- FU, oxaliplatin, and 
bevacizumab) will be assessed by the investigator as:  
Related  A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the treatment, unlikel y to be attributed to 
concurrent disease or other drugs or chemicals, which follows a clinically 
reasonable response on withdrawal (de -challenge), and which is definitive 
pharmacologically or phenomenologically ( i.e., an objective and specific medical 
disorder or a recognised pharmacological phenomenon).  Re -challenge 
information may be required to fulfil this definition.  
Probable  A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the treatment, unlikely to be attributed to 
concurrent disease or other drugs or chemicals, and which follows a clinically 
reasonable response on withdrawal (de -challenge).  Re -challenge information is 
not required to fulfil this definition.  
Possible  A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to treatment, but which could also be explained by concurrent disease or other drugs or chemicals.  Information on IMP withdrawal may be lacking or uncle ar. 
Unlikely  A clinical event, including laboratory test abnormality, with a temporal 
relationship to treatment which makes a causal relationship improbable, and in 
which other drugs, chemicals, or underlying disease provide plausible 
explanations.  
Not A pplicable  Expected only when  the drug has not  been  administered.  
For SUSAR reporting , the three following criteria, Related , Probable  and Possible  will correspond to 
the criteria â€œ Reasonable possibility of a causal relationship â€. The Unlikely  criteria will correspond to 
the criteria â€œNo reasonable possibility of a causal relationship â€. 
 
8.4.3.3  E XPECTEDNESS  
 Expected adverse reactions are AEs that are known to occur for the study intervention  being studied.  
Expectedness is assessed based on the awareness of AEs previously observed, not on the basis of what might be anticipated from the properties of the study intervention.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 54 An adverse reaction is considered as unexpected if the nature or severity of this is n ot consistent 
with the applicable product information presented in the Investigator's Brochure or in a summary of 
product characteristics (SPC) for an authorized product.  
The IB  presents a review of the safety data from clinical trials which identified fat igue and nausea as 
the most common ARs. However, they were no more frequent than could be expected for the same 
cytotoxic agents in the presence of other folates.  
The Sponsor  will be responsible for determining whether an S AE is expected  or unexpected .  An SAE 
will be considered unexpected if the nature, severity or frequency of the event is not consistent with the risk information previously described.  
 
8.4.4  T
IME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
AEs and SAEs will be reported  in the eCRF  from the time of signing informed consent form until End 
of Treatment visit, whether or not considered to be drug related .  
â€¢ From the time of signing informed consent form until randomization, only  AEs causing the 
patient to drop out of the stu dy or being related to study procedure  will be reported in the 
eCRF.   
â€¢ After  the End of Treatment visit, only SAEs  related to study specific procedures  or considered 
to be at least possibly related to study drug should be recorded  
All SAEs  and AESIs  will be  entered in the eCRF and  followed until satisfactory resolution or until the 
site Investigator deems the event to be chronic or the participant is stable. Other supporting 
documentation of the event may be requested by the study sponsor and should be provided as soon 
as possible.  
Before database closure, reconciliation between the SAEs entered in the safety database and the study database will be performed.  
8.4.5  A
DVERSE EVENT REPORTING  
AEs reported by the patient  or observed by the Investigator will be individually listed in the  eCRF. 
Including diagnosis, signs and symptoms  (if a diagnosis is not available), date of onset, duration, action 
taken, severity, outcome to date, relationship to any of the treatment regi men drugs  or study 
procedure and seriousness  will be recorded. The severity of AEs will be graded according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI -CTCAE  Version 5.0 ) 
toxicity criteria.  
At each visit, the Invest igator  will be prompted to report  causality of  AEs as â€œ Related â€, â€œProbable ,â€ 
â€œPossible â€ or â€œUnlikelyâ€  related to the IMP,  any anti-cancer  treatment regimen or study procedure . 
8.4.6  A DVERSE EVENT OF SPECIAL INTEREST   
AEs related to mucositis and bone marrow toxicity will be followed as AESIs  in this study, to ensure 
that there are no significant safety issues when arfolitixorin , instead of Leucovorin,  is combined with 
5-FU in the mFOLFOX -6 + Bevacizumab regimen . AESI w ill be followed as ordinary AEs but reported 
separately in the study report as described in the SAP.  
8.4.7  S ERIOUS ADVERSE EVENT REPORTING  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 55 The reporting of SAEs will be done through the eCRF. Only in the event of the eCRF not being available 
SAEs should be repo rted by fax or e -mail on the paper SAE report form found in the Study File.  
Fax: +33 (0) 467 107 253 
or 
Email: isofol-safety@vigipharm.fr  
The Investigator  is responsible for ensuring that all SAEs are reported to the Sponsor  immediately, but 
in any event no later than 24 hours of any site staff becoming aware of the event.  Initial reports should be followed as soon as possible by detailed reports.  The initial and follow -up reports should identify 
patients by unique study code (Study ID) . The patientsâ€™ names, personal identification numbers, and 
addresses must not be included in the report . The following information is mandatory for the initial 
report:  
â€¢ Patient Study ID  
â€¢ Study treatment  
â€¢ Start date (time, if relevant) of the study treatment  
â€¢ Brief description of the event (diagnosis, or signs/symptoms if diagnosis is not available ) 
â€¢ Start date (time, if relevant) of the event  
â€¢ Seriousness criteria  
â€¢ Causality assessment  
Detailed instructions describing the procedure of reporting SAEs including SUSARs will be distributed to the site and all involved parties . 
For reported deaths, the Investigator  should supply the Sponsor  and the IRB/IEC  (if applicable) with 
any additional requested information ( e.g., autopsy reports and t erminal medical reports).  
The investigator  is responsible to report the events to the Sponsor according to the protocol to allow 
the Sponsor to meet their SUSAR reporting obligations. The Sponsor is responsible for reporting SUSARs to the competent authorities.  The IRB/IEC will be informed according to local requirements 
by either the Sponsor or the PI.   
8.4.8  REP
 ORTING EVENT S TO PARTICIPANTS  
Sponsor  will inform Investigators of any SUSAR , discovered in this or in any other study during the 
study period . It is the investigators responsibility to inform the patients if deemed necessary.  
8.4.9  REP ORTING OF PREGNANCY  
Female patients will be instructed to notify the Investigator  immediately if they become pregnant 
during the study.  Male patients will be instructed to notify the Investigator  immediately if their 
partner becomes pregnant.  Pregnant patients will be withdrawn from further study treatment.  The patients will also be  instructed to report pregnancies discovered after the last visit if they believe that 
conception occurred during their participation in the study.   
A pregnancy is not an AE, unless there is a possibility that the IMP has interfered with the efficiency of any contraceptive measures.  However, the Investigator  should report pregnancies according to the 
procedures and timelines described for reporting of SAEs . The pregnancy report form should be used 
instead of the SAE form.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 56 Pregnant patients or partners will be followed until the end of the pregnancy.  Any complication during 
the pregnancy will be reported as an AE.  The outcome of the pregnancy must be reported on the 
pregnancy report form.  Any spontaneous abortion, stillbirth, birth defect/congenital anomaly, death, or other serious infant condition must be reported and followed up as an SAE.  
 
 
 
9 STATISTICAL CONSIDERATIONS  
 
9.1 STATISTICAL HYPOTHESES  
The primary end -point is ORR. Null and alternative hypotheses are  expressed in terms of âˆ† ORR, the 
difference in ORR between the randomized treatment arms :  
â€¢ H0: âˆ†ORR=0  
â€¢ H1: âˆ†ORRâ‰¥15%  
 
 
9.2 SAMPLE SIZE  DETERMINATION  
 
9.2.1  P RIMARY EFFICACY ENDPOINT: ORR  
 
For this adaptive design, the initial sample size calculation is based on an improvement by 15% in ORR; specifically, ORR is assumed to be 45% in the control arm vs. 60% in the experimental arm. It is assumed that up to 10% of patients will be unevaluable for response in both treatment arms. These patients will be considered non -responders and will not contribute to  the difference between 
experimental and control (hence the expected difference is 13.5% rather than 15%). For a two -sided 
test with ð›¼ð›¼=0.05 and a power of 80% to detect this difference, at least 440 patients need to be 
randomized. At a sample size of 330 (75% of the information fraction for ORR), interim results will be 
used for adaptive sample size re -estimation, based on the conditional power for both ORR and PFS, 
without a formal interim analysis of efficacy or futility. This is detailed in the interim analysis plan. The statistical design allows for a 50% sample size increase (to 660 patients), should interim results be promising enough to warrant such a sample size increase.  In case the sample size is increased, 
this provide s 94% power to detect th e same difference, i.e. 13.5%, for ORR . 
 Initially, approximately 440 were planned to be randomized. However, Japanese authorities 
requested that approximately 12.7% of the total study population are enrolled from Japan. For this 
reason, additional patients from Japan were randomized. In the end a total of 490 patients were  
randomized. This decision to randomize extra Japanese patients was made  before the interim 
analysis. The decision to include the Japanese patients in the ITT population (see Section 9.2. 2) for 
the primary efficacy analysis was made  after the interim analysis. The addition of extra Japanese 
patients leads to a statistical power greater than 80%.  
 Blinded Independent Central Review (BICR) is the process by which radiographic exams obtained as part of a clinical study are submitted to a central location for review by independent physicians who are not involved in the clinical study. Regulatory authorities have recommended BICR of all patients 
(or a cohort of patients) for oncology registratio n studies when the primary study endpoint is based 
on tumor measurements, such as PFS, DOR or ORR [ 31]. 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 57  
As the ISO -CC-007 study is an open -label study, it is essential to keep the assessors for the primary 
endpoint blinded to treatment allocation.  
 
The comparator arm in the ISO -CC-007 study consist of Leucovorin, administered together with 5 -
FU, oxaliplatin (the mFOLFOX -6 regimen) + bevacizumab. The efficacy for this treatment 
combination has been assessed by blinded independent central review only in a few clinical Phase III 
studies [14, 2 7]. The ORR in these trials range from 38 to 48 %. For the ISO -CC-007 study, we have 
therefore assumed an ORR of 45% for the comparator arm.   
 
9.2.2  S ECONDARY EFFICACY ENDPOINT: PFS  
 The study is also powered to detect a hazard ratio of 0.725, which corresponds to a clinically 
meaningful difference in PFS (median PFS equal to 10 months in the control arm vs. 13.8 months in 
the experimental arm).  For a power of 80%, 300 PFS events need to be observed  using a 1- sided 
ð›¼ð›¼= 0.025. The statistical design allows for a 50% sample size increase (to 660 patients), should 
interim results be promising enough to warrant such a sample size increase. In case the sample size 
is increased, the target number of events will be increased to 450 PFS events, which provides 80% 
power to detect a hazard ratio of 0.77 (median PFS equal to 10 months in the control arm vs. 13 months in the experimental arm).  
 At the time of writing of this protocol amendment, the interim analysis with the possibility of an adaptive sample size increase, already took place. The DSMB did not advice to increase the sample 
size. Furthermore, as the number of patients censored because of new anti -cancer therapies , was  
higher than expected, it became clear during the study that the 300 PFS events could not be 
reached.  Therefore it was decided to include all Japanese patients in the ITT population, increasing 
the total sample size  from the planned 440  to 490 patients in total , and to decrease the number of 
PFS events at the final analysis from 300 to  at least  235.  
Table 4  shows, for 300 and 23 5 PFS events, the hazard ratio for which the trial wo uld have 80% 
power, the hazard ratio for which the trial would just reach statistical significance, and the corresponding median PFS in the treatment arm, assuming a 10 -month median PFS in the control 
arm.  
 
Table  4: Hazard ratio for significance in function of the number of PFS events   
 Design  Final analysis  
Number of 
PFS events  Median PFS  
Control arm  Hazard 
ratio  Median PFS  
Treatment arm  Hazard ratio for 
significance  Median PFS  
Treatment arm  
300 10 months  0.725  13.8 months  0.80  12.5 months  
235 10 months  0.692 14.5 months  0.77  12.9 months  
 
A hazard ratio of 0.77  was considered a clinically relevant threshold for statistical significance.  The 
final PFS analysis will therefore be performed when at least 235 PFS events will be reached.  
 
PFS analysis will be based on the randomized treatment. The censoring rules and details of the 
sensitivity analyses are specified in the study specific statistical analysis plan.   
9.2.3  H IERARCHICAL TESTING APPROACH 
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 58 A fixed sequence hierarchical test procedure will be applied, with a pre -defined order in which the 
hypotheses are to be tested. Each test will be performed without a multiplicity adjustment for 
multiple endpoints, i.e. at the nominal ð›¼ð›¼ -level foreseen by the group sequential design. The 
secondary endpoint PFS can only be tested formally after the first hypothesis, i.e. the null hypothesis 
for ORR, is rejected at the final analysis.  
 
9.2.4  O VERALL SURVIVAL  
 
An analysis of OS at the same time as the final PFS analysis has a 30% power to demonstrate a hazard ratio of 0.8 (corresponding to a median OS equal to 25 months in the control arm vs. 31.25 months in the experimental arm), when approximately 180 events are observed, using a 1 -sided 
Î±=0.025. If the sample size is increased to 660 patients, analyzed at the same time as the final PFS 
analysis , this power is increased to 45%, when approximately 270 events are observed. The addition 
of the extra Japanese patients (see Section 9.2.2) to the 440 initial patients, resulting in a total number of 490 randomized patients, leads to a statistical power slightly greater than 30%.  No 
interim efficacy analysis is foreseen for OS. Note that this trial is underpowered for OS, and that there is no intention to claim efficacy for OS.  
 Given the key relevance of this endpoint in an overall assessment of benefit/risk, it is important to power the OS analysis to exclude a significant detrimental effect of arfolitixorin  as compared to 
leucovorin in terms of OS. The OS analysis is based on the following considerations:  
 1) Collection of vital status will continue in all randomized patients after the final PFS analysis, until 
the OS analysis. Of note, the aim for this continued follow -up is to monitor the patientsâ€™ safety, 
rather than showing superior efficacy of arfolitixorin  in terms of OS.  
2) Arfolitixorin is not expected to cause serious toxicity. It is therefore reasonable to assume that if 
superior efficacy of arfolitixorin  is demonstrated, OS is unl ikely to be inferior in the arfolitixorin arm 
compared to the leucovorin arm. The magnitude of the OS difference is hard to predict, for example due to  the multiple lines of active therapies currently available for the treatment of patients with 
advanced c olorectal cancer. Assuming similar post -progression survival in both trial arms, a 
reasonable assumption is that the difference in median PFS between arms will â€œcarry overâ€ to the difference in median OS.  
3) A â€œsignificant detrimental effect on OSâ€ will b e taken equal to the benefit of leucovorin estimated 
in the meta -analysis of all trials comparing 5 -fluroruracil alone with 5 -fluroruracil + leucovorin [33]. 
The overall OS HR of leucovorin was equal to 0.9 in these trials; hence, an  OS hazard ratio equal to 
1/0.9 = 1.11 in the current trial may be considered a significant detriment, to the extent that it will outweigh the benefit observed historically with leucovorin.  
4) Collection of vital status will continue after the ORR and PFS analysis, until 60% of the patients 
have had a death event. If the trial accrues 490 patients, 294 deaths , or 60% of 490 , will be 
observed . 
 
9.2.5  A
CCRUAL RATE  
 The accrual rate will be assumed to ramp up as follows: 2, 3, 7, 11, 14, 22 and 25 patients 
respectively in the 1st to 7th months after study start, and 28.8 patients monthly thereafter.  
 
9.3 POPULATIONS FOR A NALYSES  
 All enrolled patients who were randomized will be included in the analyses. The following  
analysis datasets will be considered : 
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 59 â€¢ Intention- to-Treat (ITT) analysis set consists of all randomized participants. Analyses will 
be based on the randomized treatment.  
â€¢ Intention- to-Treat Excluding Additional Japanese Patients (ITTE ) analysis set consists of 
all randomized participants  excluding additional Japanese patients . Analyses will be based 
on the randomized treatment.  
â€¢ Per-Protocol (PP) analysis set defines a sub set of the participants in the ITT  
analysis set without major protocol deviations. The definition of major protocol  
deviations will be agreed upon, and all cases of such major deviations adjudicated  prior to 
database lock. Analyses will be based on the ran domized treatment.  
â€¢ Safety analysis set defines the subset of participants for whom safety analyses will be 
conducted. It includes all  patients who received at least one dose of study medication. 
Analysis will be based  on the actual treatment.  
â€¢ PK analys is set defines a subset of the participants in the Safety analysis set for  
whom PK samples were analyzed. Analyses will be based on the actual treatment.  
 
9.4 STATISTICAL ANALYSES  
 
9.4.1  G ENERAL APPROACH  
 
Categorical data will be summarized in contingency tables presenting frequencies and percentages. Continuous data will be summarized using number of non -missing values (n), mean, standard 
deviation, median, minimum and maximum values. Significance tests will be performed at the Î± = 0.05 significance level for two -tailed tests and at Î± = 0.025 for one- tailed tests. Methods to calculate 
confidence intervals will be specified in Statistical Analysis Plan.   
 
9.4.2  A
NALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
 
The primary end -point is ORR  based on BICR assessment of C T/MRI scans , and will be analyzed both 
for the ITT and PP population.  
ORR will be analyzed using a Cochran -Mantel -Haenszel test (CMH), stratified for the stratification 
factors used for randomization (geographic region, primary tumor location and previous  neo-
adjuvant/ adjuvant CRC treatment) .   
 
9.4.3  A NALYSIS OF THE SECONDARY ENDPOINT(S)  
 Secondary efficacy endpoints are PFS, DOR , OS, quality of life (EQ -5D questionnaire) , curative 
metastasis resection,  and safety and tolerability (including PRO CTCAE) .   
 PFS and DOR  will be based on BICR assessment of the patients CT/MRI scans. PFS, DOR  and OS will be 
analyzed using Kaplan -Meier curves, the logrank test and a stratified Cox proportional hazards model, 
using the same stratification factors as for randomization (geographic region, primary tumor location 
and previous neo -adjuvant/ adjuvant CRC treatment) . The assumption of proportional hazards will be 
tested. In addition to the p- value, based on a stratified logrank test, and the Hazard Ratio (with 95%CI), 
desc riptive statistics will also be presented for time to event endpoints  (Number of patients used for 
analysis, number of events, median months to event and 95%CI).  
 
The EQ -5D questionnaire results will be analyzed in a descriptive way, e.g. by means of grap hical 
representation . Number of p atients undergoing curative metastasis resection will be compared 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 60 between the treatment groups.  Further evaluation of the results will be specified in the statistical 
analysis plan  which will be in place before including the first patient in the study .  
 
 
9.4.4  S AFETY ANALYSES  
 
Safety variables include the reported AEs, SAEs, laboratory tests, vital signs and physical examination. 
AEs will be coded and evaluated for severity using NCI -CTCAE Version 5.0 and will be summarized by 
MedDRA system organ class and preferred term. Separate summaries and listings will include the following:  
â€¢ All adverse events  
â€¢ Adverse events of CTC grade â‰¥3  
â€¢ Related adverse events  
â€¢ Fatal adverse events  
â€¢ Discontinuations due to adverse events or deaths  
â€¢ Serious adverse events  
â€¢ Deaths on IMP  treatment or within 30 days of study drug discontinuation  
â€¢ Patient reported outcome on specific AEs on PRO  CTCAE  (See Appendix 2) for countries where 
valid translations are available (See Appendix 2)  
 
The NCI PRO -CTCAE  questionnaire results will be analyzed in a descriptive way, e.g. by means of 
graphical representation. Further evaluation of the results will be specified in the statistical analysis 
plan .  
 
Laboratory test s will be summarized at each timepoint, including change from baseline. Summaries 
will be presented separately for hematology, blood chemistry  and urinalysis parameters. Other safety 
data (vital signs, physical examination ) will also be tabulated and liste d.  
 
9.4.5  B
ASELINE DESCRIPTIVE STATISTICS  
 
The study treatment groups will be compared on baseline characteristics, including demographics 
and laboratory measurements, using descriptive statistics. No inferential statistics will be used.  
 
9.4.6  P LANNED INTERIM AND FI NAL  ANALYSES  
 
9.4.6.1   AN ALYSIS PLAN  
The trial design will include the following analyses (and adaptations if indicated):  
â€¢ Based on the interim results of 330 patients (75% information fraction for ORR), who have a 
follow -up of at least 16 weeks , the DSMB  may recommend a 50% sample size increase (from 
440 to 660 patients)  according to the guidelines  in Table 5.  
â€¢ if the sample size is not increased:  
o the final analysis of OR R and PFS  will take place after approximately  34 months with 
300 PFS events  
â€¢ if the sample size is increased:  
o the final analysis of ORR  and PFS will take place after approximately 38 months with 
450 PFS events   
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 61 At the time of writing of this protocol amen dment, the interim analysis with the possibility of an 
adaptive sample size increase, already took place. The DSMB did not advice to increase the sample 
size. Furthermore, as the number of patients censored because of new anti -cancer therapies , was  
higher than expected, it became clear during the study that the 300 PFS events could not be 
reached.  Therefore it was decided to include all Japanese patients in the ITT population, increasing 
the total sample size from the planned 440 to 490 patients in total, and to decrease the number of 
PFS events at the final analysis from 300 to  at least  235 (see also Section 9.2.2).  
 
9.4.6.2  IN TERIM ANALYSIS  
 An interim analysis will be performed when 16 -week BICR evaluation has been performed for the 
330th patient. For the  interim analysis of ORR, the significance level will be determined using a Rho 
spending function, with ðœŒðœŒ = 5, resulting in a very conservative boundary.  Assuming an information 
fraction of 75% for ORR at this interim analysis, the 1 -sided significance level for efficacy will be 
0.006, and it will be reached if the difference in ORR is larger than 13.8%. This small alpha spending is foreseen to take into account the interim look at the efficacy primary endpoint, i.e. ORR. However, there is no intention to c laim efficacy for ORR at this stage. The interim results, i.e. the conditional 
power for both ORR and PFS, will only serve to guide the decision rules regarding sample size re -
estimation. Results of this analysis will remain blinded to everyone, except the  DSMB. Regardless of 
the efficacy results of the interim analysis, the trial will continue to accrue patients, until the total planned sample size is reached.  
 As for ORR, there is no intention to claim efficacy for PFS at this early stage either. A small alpha 
spending is foreseen to take into account the interim look. For  this, a very conservative Rho 
spending function boundary, with ðœŒðœŒ= 5, is used. Assuming an information fraction of 37% for PFS at 
this interim analysis, the 1 -sided significance level for efficacy will be 0.000173, and it will be 
reached if the hazard ratio is less than 0.51.  
 
9.4.6.3  SAM
 PLE SIZE ADAPTATION  
 
The conditional power for both ORR and PFS will be calculated at the interim analysis, assuming  
that the estimated treatment difference at interim analysis is the true effect. Depending on the 
conditional powers, the trial will either continue as planned to accrue 440 patients, or the sample 
size of the trial will be increased by 50%, for a total sample size of 660 patients. The guidelines provided in Table 5 will be used by the DSMB  to make a recommendation to the Sponsor . Two 
possible decisions can be communicated to the Sponsor by the DSMB: â€œsample size increaseâ€ or â€œno sample size increaseâ€.  
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 62 Table 5: Guidelines for sample size increase at interim analysis  
ORR = overall response rate; PFS = progression -free survival S=Success, F=Failure, CP=Conditional 
Power assuming that the estimated treatment difference at interim analysis is the true effect, 
CP440= conditional power at N=440, CP660= conditional power at N=660.  m=months,  NA=not 
applicable  
* Including type I error rate adjustment, using the Cui, Hung and Wang method  [32] 
 
The conditional power for ORR would be equal to approximately 80% if the observed difference in ORR, at the time of the interim analysis (75% information fraction) were equal to 11.5%. The conditional power for PFS would be equal to 25% if the observed hazard ratio, at the time of the interim analysis (37% information fraction) were e qual to 0.85.  Note that a HR=0.85 corresponds 
with a Median survival time Control/Experiment of 10/11.75, which is considered clinically meaningful. The conditional power for PFS would be equal to 50% if the observed hazard ratio, at the time of the inter im analysis (37% information fraction) were equal to 0.80. The conditional 
power for PFS would be equal to 75% if the observed hazard ratio, at the time of the interim analysis (37% information fraction) were equal to 0.75.  
   ORR  PFS 
Recommendation  CP660 for  
CP440  Observed 
ORR 
difference  CP440  Observed HR  
ORR  PFS 
â‰¥ 80%  â‰¥11.5%  â‰¥ 75%  â‰¤0.75  
(â‰¥3.3 m)  Continue trial unchanged  NA NA 
50-75%  >0.75; â‰¤0.8  
(â‰¥2.5<3.3m)  Increase sample size  â‰¥ 90%  70-90%  
25-50%  >0.8; â‰¤0.85  
(â‰¥1.8;<2.5m)  Increase sample size*  â‰¥ 90%  >40-<70%  
<25%  >0.85  
(<1.8m)  Continue trial unchanged  NA NA 
60-80%  â‰¥ 10%;< 
11.5%  â‰¥ 75%  â‰¤0.75  
(â‰¥3.3 m)  Increase sample size  80-90%  â‰¥90%  
50-75%  >0.75; â‰¤0.8  
(â‰¥2.5<3.3m)  Increase sample size  80-90%  70-90%  
25-50%  >0.8; â‰¤0.85  
(â‰¥1.8;<2.5m)  Increase sample size*  80-90%  >40-<70%  
<25%  >0.85  
(<1.8m)  Continue trial unchanged  NA NA 
< 60%  <10%  â‰¥ 75%  â‰¤0.75  
(â‰¥3.3 m)  Continue trial unchanged  NA NA 
50-75%  >0.75; â‰¤0.8  
(â‰¥2.5<3.3m)  Continue trial unchanged  NA NA 
25-50%  >0.8; â‰¤0.85  
(â‰¥1.8;<2.5m)  Continue trial unchanged  NA NA 
<25%  >0.85  
(<1.8m)  Continue trial unchanged  NA NA 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 63 9.4.6.4  FIN AL ANALYSIS OF ORR WITHOUT SAMPLE SIZE INCREASE  
 
The final analysis of ORR  will be performed  when at least 23 5 PFS events have been observed.  The 1-
sided  significance level for efficacy will be 0.024.  
 
9.4.6.5  FIN AL ANALYSIS OF ORR WITH SAMPLE SIZE INCREASE  
 If the sample size is increased to 660 patients, the final analysis of ORR  will be performed when 450 
PFS events have been observed . The 1-sided  significance level for efficacy will be 0.025.  
 
9.4.6.6  FIN
 AL ANALYSIS OF PFS WITHOUT SAMPLE SIZE INCREASE  
 The final analysis of PFS will be performed when at least 23 5 PFS events have been observed. The 1-
sided significance level for efficacy will be 0.025.  
 
9.4.6.7  FIN
 AL ANALYSIS OF PFS WITH SAMPLE SIZE INCREASE  
 
If the sample size is increased to 660 patients, the final analysis of PFS will be performed when 450 PFS events have been observed. The 1 -sided significance level for efficacy will be 0.025.  
 
9.4.7  S
UB -GROUP ANALYSES  
 
Subgroup analyses will be performed for ORR and PFS with respect to the trialâ€™s stratification factors 
(geographic region , primary tumor location and previous adjuvant CRC treatment) and other 
prognostic factors, which will be specified in the SAP.  
 
The consistency of the treatment effect across prognostic subgroups will be assessed visually using 
forest plots.  
 
9.4.8  T ABULATION OF INDIVIDUAL PARTICIPANT  DATA 
 
Individual participant data will be listed by measure and timepoint  
 
9.4.9  EX PLORATORY ANALYSES  
 
Exploratory analyses are:  
â€¢ Daily living abilities: analyses will be descriptive.  
â€¢ Pharmacokinetic characteristics of arfolitixorin  
â€¢ To determine folate metabolism - and transportation -related gene expression levels in 
patients with advanced CRC   
â€¢ Evaluation of Recurrence Free Survival for patients undergoing complete metastatic resection.  
 
       
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 64 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 
 
10.1 REGULATORY, ETHICAL , AND S TUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1 INFORMED CONSENT PROCESS  
 
10.1.1.1  C ONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS 
Consent forms , in local language and in laymanâ€™s term s, describing in detail the study interventions , 
study procedures, and risks  and possible benefits  are given to the patient and written documentation 
of informed consent is  required prior to any study specific procedures are performed . 
The protocol, consent form(s), recruitment materials and all patient material (and any changes to 
these documents) will be submitted to the IRB/IEC for review and approval. If the Patient 
Information/Informed Consent Form is  amended, a determination will b e made regarding whether 
previously consented patients need to re- consent.  
10.1.1.2  C ONSENT PROCEDURES AND DOCUMENTATION  
Informed consent is a process that is initiated prior to the patient â€™s agreeing to participate in the study 
and continues throughout the individ ualâ€™s study participation. Consent forms will be IRB/IEC -
approved,  and the patient will be asked to read and review the document. Furthermore, the consent 
forms will include any requirements from the ethics committee. The Investigator will explain the 
rese arch study to the patient, be the primary contact person and answer any questions that may arise. 
A verbal explanation will be provided in terms suited to the patientâ€™s comprehension of the purposes, 
procedures, and potential risks of the study and of thei r rights as research patients.   Patients will have 
the opportunity to carefully review the written consent form and ask questions prior to signing. The 
patients should have the opportunity to discuss the study with their family or surrogates or think about  
it prior to agreeing to participate.  
Patients must be informed that participation is voluntary and that they may withdraw from the study 
at any time, without prejudice.  
The patients (or their legally acceptable representative or witness, as applicable) will sign and 
personally date the informed consent document prior to any study specific procedure . A copy of the 
informed consent document will be given to the patients. Another copy of the signed consent form 
will be saved in the Investigatorâ€™s file. The in formed consent process will be conducted and 
documented in the source document (including the date), and the form signed, before the patient 
undergoes any study  specific procedures. The rights and welfare of the patients will be protected by 
emphasizing to  them that the quality of their medical care will not be adversely affected if they decline 
to participate in this study.  
The informed consent includes information that data will be recorded, collected, processed and may 
be transferred to countries outside the patientâ€™s country of residence . The informed consent shall 
comply, in all respects, all applicable laws and regulations concerning personal data protection  in the 
country in which the study takes place . 
The informed consent include s information  about the intended purposes of the processing of personal 
data, the right to obtain access to personal data, the right to correct incorrect personal data, the right 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 65 to withdraw their consent of the processing of personal data at any time  and the right to delete 
personal data already collected in the study . 
10.1.2 STUDY DISCONTINUATION AND CLOSURE  
This study may be temporarily suspended or prematurely terminated if there i s sufficient reasonable 
cause. Written notification, documenting the reason for study suspens ion or termination, will be 
provided by the susp ending or terminating party to patient s, Investigator , and  regulatory authorities . 
If the study is prematurely terminated or suspended, the PI will promptly inform,  the IRB /IEC and , 
patients  will be contacted , if applicable. 
Circumstances that may warrant termination or suspension include, but are not limited to:  
â€¢ Determination of unexpected, significant, or unacceptable risk to participants  
â€¢ Demonstration of efficacy that would warrant stopping    
â€¢ Insufficient compliance to protocol requirements  
â€¢ Data that are not sufficiently complete and/or evaluable  
â€¢ Determination that  the primary endpoint has been met  
â€¢ Determination of futility  
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the Sponsor , IRB /IEC and/or Regulatory Authorities . 
10.1.3 C ONFIDENTIALITY  AND PRIVACY   
Patient  confidentiality and privacy is strictly held in trust by the participating Investigators, their staff, 
and the Sponsor . This confidentiality is extended to cover testing of biological samples and genetic 
tests in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No 
information concerning the study,  or the data will be released to any unauthorized third party without 
prior written approval of the Sponsor .  
The study monitor, other authorized representatives of the Sponsor , representatives of the IRB /IEC, 
regulatory authorities  may inspect all documents and records required to be maintained by the 
Investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy 
records for the participants in this study. The  clinical study site will permit access to such records.  
The patient â€™s contact information will be securely stored at each clinical site for internal use during 
the study. At the end of the study, all records will continue to be kept in a secure location f or as long 
a period as dictated by the reviewing IRB /IEC, Institutional policies, or Sponsor  requirements.  
10.1.4 F
UTURE USE OF STORED SPECIMENS AND SAMPLES   
No specimens and samples  will be used or kept after the end of the study.  
10.1.5 K EY ROLES  AND STUDY GOVERNANCE  
 
Sponsor  Sponsor â€™s Medical Expert  
Isofol Medical AB  (publ)  
Arvid Wallgrens Backe 20  
S-413 46 Gothenburg, Sweden  Roger Tell , MD, PhD  
Phone: +46 (0)  708 63 06 95 
E-mail: roger.tell@isofolmedical.com  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 66   
  
Co-ordinating Investigator  
Josep Tabernero, MD, PhD  
Spain  
Phone: +34 (0)93 489 4301  
E-mail:  jtabernero@vhio.net   
 
  
Chairman of DSMB  
Alberto Sobrero, MD, PhD  
Italy  
Phone: +33 (0) 52 567 40  
E-mail:  alberto.sobrero@hsanmartino.it  
  
 
10.1.6 SA FETY OVERSIGHT  
An independent Data  and Safety Monitoring Board (DSMB ) will be constituted . The DSMB will protect  
the safety and well-being of the patients  participating in the study and ensuring the ethical conduct 
of this clinical trial, through a regular review of the accumulated unblinded safety data reported by 
the independent DSMB statistician.  The DSMB will make  recommendations to the Sponsor or design ee 
after each meeting, regarding the continuation of the trial, modification of the protocol or any other 
changes they will judge appropriate . Closure of the study may be recommended i f the DSMB deems 
there is an unacceptable risk / benefit ratio of the participants.  
In addition, for Japan the DSMB will review PK data, safety and tolerability after completion of two treatment cycles for the first ten randomized J apanese patients, including patients from both 
treatment arms. In case of safety concerns or substantial differences in PK profile compared to the 
other study patients, the DSMB may halt the inclusion of study patients in Japan to gather more information. After review of the data, the DSMB will provide a recommendation to continue, or stop, inclusio n of Japanese  study patients.  
The DSMB  will be composed of at least three members with the appropriate expertise, including at 
least one oncologist  and one biostatistician . Members of the DSMB  are independent from the study 
conduct and free of conflicts of interests.   A D SMB  Charter, finalized before the start of the study, 
specif ies the D SMB  procedures , constitution  and statistically derived guidelines for sample size 
increase . The safety moni toring analyses by the DSMB will be conducted every six months  or more 
often if needed , commencing with completion of the first three months of study accrual. 
Recommendations from the DSMB to Sponsor  will comprise, in addition, considerations on sample 
size increase at interim analysis, as well as early termination of the study or any other relevant 
recommendations . 
10.1.7 C
LINICAL MONITORING  
In accordance with applicable regulations including GCP, study monitors will contact the site prior to the start of the study to review with the site staff the protocol, study requirements and facilities , and 
their responsibilities to satisfy regulatory, ethical, and Sponsor  requirements.  
Study monitors will be delegated responsibility to monitor the study and site activity to verify that the:  
â€¢ Data are authentic, accurate, and complete;  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 67 â€¢ Safety and rights of patient s are being protected; and  
â€¢ Study is conducted in accordance with the currently approved protocol and any other study 
agreements, GCP, and all applicable regulatory requirements.  
â€¢ Data collection is accurate and reliable which will be assured by verification and cross -check 
of selected data in the eCRFs against the Investigator â€™s records by the study monitor (source 
document verification).  
â€¢ Location of source d ocuments are clearly identified.  
The monitor will contact and visit the Investigator  regularly and must be permitted access to all source 
documents needed to verify the entries on the eCRF and other protocol -related documents, provided 
that patient  confide ntiality is maintained in accordance with local regulations. It will be the monitorâ€™s 
responsibility to inspect the eCRFs at regular intervals throughout the study, to verify adherence to the protocol and the completeness, consistency and accuracy of the data being entered on the eCRFs.  
Sponsor  or CRO monitoring standards require full verification that informed consent has been 
provided, and verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main e fficacy, safety and tolerability endpoints. Additional checks of the 
consistency of the source data with the eCRFs will be performed according to the Clinical Monitoring Plan (CMP) . Any data reported in the eCRF must be verifiable in the site source documents , if not 
clearly specified that the eCRF can be the source for a specific data point .  
Details of clinical site monitoring are documented in a CMP. The CMP describes in detail who will conduct the monitoring, at what frequency monitoring will be done, a t what level of risk -based  
monitoring and SDV will be performed, and the distribution of monitoring reports  
The Investigator  must ensure that patient  anonymity is maintained. On  CT-scans, MRI s, lab reports  or 
other documents submitted to Sponsor  or to other parties o utside the study site , patients  must be 
identified by assigned study ID number  only , and never by name  or other identifiable information . The 
Investigator must keep a patient  identification code  list showing the patient â€™s name, date of birth, or 
any other locally accepted identifiers. Documents identifying the patient s (e.g., signed informed 
consent forms) should not be sent to Sponsor , and must be kept in strict confidence by the 
Investigator. 
The Investigator and co -Investigators agree to cooperate with the monitor(s) to ensure that any issues 
detected in the course of these monitoring visits are resolved. If the patient  is hospitaliz ed or dies in 
a hospital other than the study site, the Investigator  is responsible for contacting that hospital in order 
to document the SAE.  
The Investigator must on request supply the Sponsor  with any required background data from the 
study documentatio n or clinical records. This is particularly important when errors in data 
transcription are suspected. In the case of special problems and/or governmental queries, it is also 
necessary to have access to the complete study records, provided that patient  confidentiality is 
protected.  
10.1.8 QU
ALITY ASSURANCE  
This study will be conducted in compliance with the protocol , the ICH Guideline for GCP, and an y 
applicable local regulations  (for US sites, the study will be conducted under an IND) . Sponsor  is 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 68 responsible for independent quality assurance (QA) audits of the clinical study processes, if deemed 
appropr iate. Audit of the study sites may be conducted to assess and help assure compliance with 
GCP and appli cable regulatory requirements. The study sites may be subject  to a QA audit by Sponsor  
or its representatives, may be reviewed by an independent QA department, or may be inspe cted by 
regulatory authorities. Auditors/inspectors will have the right to inspect the study sites at any time 
during and/or after completion of the study and will have access to source documents, including patientsâ€™ medical records . By participating in this study, the Investigator agre es to this requirement.  
10.1.9 DA
TA  HANDLING  AND  RECORD  KEEPING   
 
10.1.9.1  P ERSONAL DATA PROTECTION  
 
Patient personal data will be collected and processed in this study to answer the scientific questions investigated. The legal basis for the processing of personal data is the informed consent collected 
from all patients. Patients are informed about their rights connected to the processing of their 
personal data in the informed consent process.   
The Sponsor is the controller of all personal data recorded, collected and processed in this study. The Sponsor follows applicable laws and regulations concerning personal data protection in the countries where the study is being conducted. All personal data processed by the Sponsor is coded, and the Sponsor does not know the identity of the individual patients (this information will only be available at the study s ite of the respective patient).  
The sites are responsible for handling of their patientsâ€™ personal data collected as part of the patientâ€™s treatment. The Sponsor is responsible for the processing of the coded data received from the sites. Both sites and the Sponsor will take the necessary measures in order to comply with all applicable Data Protection laws.
  
Coded patient  data  for statistical analysis and scientific reporting, will be transmitted to  various 
recipients (Sponsor, and sponsor representatives, Health Authorities, IRB/IEC, or other participating clinical study sites ). The transferred data will not include the participantâ€™s contact or identifying 
information. Individual participants and their research data will be identified by a unique identification 
number. The Sponsor is not able to un -identify the code, as the key to the code is available to 
designated study staff at each clinical site only. The study data entry and study management systems 
used by clinical sites and by the Sponsor  will be se cured and protected  with a personal password . 
Isofol Medical has set up appropriate restrictions and controls to ensure that patient data remains 
protected. If study data is transferred to the US, it will only be transferred to companies who 
participate in  and comply with the so -called Privacy Shield, which is an agreement between EU and 
USA for the protection of personal data in the US.  
The Sponsor has an integrity policy for clinical studies. This policy includes  details of the legal basis for 
processing of personal data and the Data Protection Officer appointed at the Sponsor (contact 
information can be found in this protocol and on the Sponsorâ€™s website).  
10.1.9.2  D
ATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
An eCRF will be used to record all data required by  the protocol,  
Prior to the start of the study, the Investigator will complete a "Delegation of significant study -related 
duties" form, defining any person who is authorized to make or change entries in the eCRF and any 
person authorized to sign the eCRF.   
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 69 Role -specific t raining sessions will be completed before a person will be granted access to the eCRF  
(e.g. Investigators and site staff, Sponso r staff and contract research organization staff, including 
project managers, clinical research associates and data managers).  
Support is available in the form of general eCRF user man uals (monitor and site manuals)  and study 
specific Data Entry Instructio ns. 
The eCRF used for this study is validated and fulfils the ICH GCP requirements, and European , US FDA 
(21 CFR Part 11) , Australian and Japanese  regulations. The data capture system includes password 
protection and internal quality checks, such as automatic range checks, to identify data that appear 
inconsistent, incomplete, or inaccurate. Clinical data will be entered directly , or from defined  source 
documents  by an authorized person . 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation 
of data.  Hardcopies of the study visit worksheets may  be provided for use as source document 
worksheets for recording data for each patient enrolled in the study. Data recorded in the eCRF 
derived from source documents should  be consistent with the data recorded on the source 
documents. The Investigator  is responsible for the management and accuracy of the information in 
the eCRF. At each monitoring visit, the eCRF should be at  the monitorâ€™s  disposal for review.  
Changes to the  data in the eCRF must  be made at the site by an authorized person.  The eCRF will have 
an audit trail with appropriate functionality for data capture, tracking, and documentation of any queries or changes.  Electronic signatures will be used to lock the data and identify the person entering or changing the data.  
Before database closure, reconciliation between the SAEs entered in the safety database and the study database will be performed.  
10.1.9.3  S
TUDY RECORDS RETENTION  
Following closure of the study, the Investigator or the head of the medical institution (where 
applicable) mus t maintain all site study records, except for those required by local regulations to be 
maintained by someone else, in a safe and secure location. The records must be maintained to allow easy and timely retrieval, when needed (e.g., audit or inspection), a nd, whenever feasible, to allow 
any subsequent review of data in conjunction with assessment of the facility, supporting systems, and staff. 
Sponsor  will inform the Investigator/institution of the required time period for retaining these records 
in order t o be compliant with all applicable regulatory requirements. The minimum retention time will 
meet the strictest standard applicable to that study site, as dictated by ICH GCP E6 Section 4.9, any 
institutional requirements or local laws and regulations, or S ponsor standards/procedures.  
The Investigator  must notify Sponsor  of any changes in the archival arrangements, including, but not 
limited to, the following: archival at an off- site facility, transfer of ownership of the records in the 
event the Investigato r leaves the site. In addition, the Investigator should seek the written approval 
of the Sponsor  prior to disposing any of the archived records.  
10.1.10  P
 ROTOCOL DEVIATIONS  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 70 A protocol deviation is any noncompliance with the clinical trial protocol or ICH GCP. The 
noncompliance may be either on the part of the patient , the Investigator , or the study site staff. As a 
result of deviations, corrective actions are to be developed by the site and implemented promptly.  
These practices are consistent with ICH GCP :  
â€¢ 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
â€¢ 5.1 Quality Assurance and Quality Control, section 5.1.1  
â€¢ 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
It is the responsibility of the site Investigator  to use continuous vigilance to ide ntify and report 
deviations within 7 working days of identification of the protocol deviation. All deviations must be 
documented and reported to Sponsor . If relevant, p rotocol deviations must be sent to the reviewing 
IRB/IEC  per their policies. The site In vestigator is responsible for knowing and adhering to such IRB/IEC 
requirements.  
10.1.11  P UBLICATION AND DATA SHARING POLICY  
Upon finalization of the ORR and PFS analysis, an integrated clinical and statistical study report will be 
written by the Sponsor  in consultation with the Coordinating Investigators. This report will be based 
on the items detailed in this study protocol. When the clinical study report is completed, S ponsor  will 
provide the Investigators with a full summary of the study results. The Investigator s are encouraged 
to share the summary results with the patients, as appropriate.  
An update of the study report will be done when the follow -up is completed incl uding overall survival 
results.  
The first resulting publication will be a full publication of all data from all participating sites, 
coordinated by Sponsor . Any secondary publications by the Investigator s (abstracts in journals, oral 
presentations etc. ) will reference the original publication and will require pre -submission review by 
the Sponsor . Note that the Sponsor  is entitled to delay any proposed secondary publication, in order 
to obtain patent protection, if required.  
Authorship for Investigator s will be assigned on the basis of their recruitment contribution, as well as 
intellectual and administrative input. Ranking will be according to the number of patients randomized as well as contribution to the study conduct and preparation of final manuscript.  
10.1.12  I
 NSURANCE  
Patients will be covered under Sponsorâ€™s liability insurance policy throughout the course of the study. The certificate of insurance will be available in the Investigator Study File at each study site and may be provided upon request. The partic ipating patients are also protected in accordance with national 
regulations as applicable. Essential information about the insurance coverage will be provided to the participating patients through the Informed Consent process.  
10.1.13  CON
 FLICT OF  INTEREST  POLICY  
The independence of this study from any actual or perceived influence, such as by the pharmaceutical industry, is critical. Therefore, any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any as pect of this trial will be disclosed and managed. Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a way that is appropriate to their participation in the design and conduct of this t rial. The study 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 71 leadership has established policies and procedures for all study group members to disclose all conflicts 
of interest and will establish a mechanism for the management of all reported dualities of interest.  
Certification and disclosure of any applicable financial interests of all clinical investigators shall be done per the requirements of 21 CFR 54 (Financial Disclosure by Clinical Investigators).  
  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 72 10.2 ABBREVIATIONS  
 
5-FU 5-fluoroucacil  
AE Adverse Event  
AESI  Adverse Event of Special Interest  
ALT Alanine Transaminase  
ANC  Absolute Neutrophil Count  
API Active Pharmaceutical Ingredient  
AST Aspartate Transaminase  
BICR  Blinded Independent Central Review  
BOR  Best Overall Response  
CFR Code of Federal Regulations  
CR Complete Response  
CRA Clinical Research Associate  
CRF Case Report Form  
CSP Clinical Study Protocol  
CTCAE  Common Terminology Criteria for Adverse Events  
DOR  Duration of Response  
DPD  Dihydropyrimidine Dehydrogenase  
DSMB  Data  and Safety Monitoring Board  
EC Ethics Committee  
ECG Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case Report Forms  
EGFR  Epidermal Growth Factor Receptor  
EMA  European Medicines Agency  
EORTC  European Organization for Research and Treatment of Cancer  
EOT End of Treatment Visit  
ESMO  European Society for Medical Oncology  
FDA Food and Drug Administration  
FFPE  Formalin -Fixed Paraffin -Embedded  
FP Fluoropyrimidine  
GCP Good Clinical Practice  
GDPR  General Data Protection Regulation  
GLP Good Laboratory Practices  
GMP  Good Manufacturing Practices  
HDMTX  High Dose Methotrexate  
IB Investigator â€™s Brochure  
ICH International Council for  Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use  
IMP Investigational Medicinal Product  
IRB Institutional  Review Board  
IRC Independent Review Committee  
ITT Intention -To-Treat  
IWRS  Interactive Web Response System  
LV Leucovorin  
mCRC  Metastatic Colorectal Cancer  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI Magnetic resonance imaging  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 73 MTHF  Methylene Tetrahydrofolate  
ORR  Overall  Response Rate  
OS Overall Survival  
PD Progressi ve Disease  
PFS Progression -Free Survival  
PI Principal Investigator  
PK Pharmacokinetic  
PR Partial Response  
QA Quality Assurance  
PRO  Patient Reported Outcome  
RECIST  Response Evaluation Criteria In Solid Tumours  
RR Response Rate  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SD Stable Disease  
SOA  Schedule of Activities  
SOC System Organ Class  
SOP Standard Operating Procedure  
SPC Summary of Product Characteristics  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TAP Thorax Abdomen Pelvis  
THF Tetrahydrofolate  
TS Thymidylate Synthase  
ULN  Upper Limit of Normal  
UP Unanticipated Problem  
VEGF  Vascular Endothelial Growth F actor  
WHO  World Health Organization  
 
  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 74 10.3 PROTOCOL  AMENDMENT  HISTORY  
 
Version  Date  Description of Change  Brief Rationale  
1.0 21Sep2018  Initial version  Initial version  
2.0 21Sep2018  In case of Oxaliplatin caused toxicity, 
dose modifications according to label 
should be performed . 
 
Update of OS analysis to exclude a 
significant detrimental effect of 
arfolitixorin  as compared to leucovorin 
in terms of OS.  FDA SPA request  
3.0 USA  13Nov2018  Inclusion criteria 3: Addition of 
leucovorin.  
 
Inclusion criteria 7: Change H gb level 
from 100 g/L to 80 g/L 
 
 
Add collection of baseline mutations in the eCRF (KRAS, BRAF, NRAS) at 
screening if available.  
 
Update of interim analysis conditions.  
 
 
 
Clarifying CT/MRI follow -up after 
metastasis resection . To clarify the components of 
standard FOLFOX treatment.  
 To align protocol inclusion criteria regarding Hgb levels with similar phase III mCRC studies.  
 
To enable sub- group analysis.  
 
 
 To avoid increasing sample size in case of poor interim study 
results.  
 
Protocol clarification.  
4.0 USA  29Aug2019  Exclusion criteria 2 and 20: Change 
from >6 months to >28 days from surgery to randomization  
 
Exclusion criteria 3: adding â€œadjuvantâ€ 
anti-cancer tre atment  
 
Oxaliplatin and Leucovorin should be 
administered in sequence or in two different injection ports.  To align protocol exclusion 
criteria regarding pre -study 
surgery with clinical praxis.  
 
Clarifying the intention of the 
exclusion criteria.  
 
To ensure study patients get full 
benefit from their oxaliplatin treatment as described in the 
SPC.  
5.0 USA  07Oct2019  Section 8.2.2.  
Clarifying ECG assessments according to the previously updated Oxaliplatin 
and Leucovorin administration.  To correct  the information  
according to the Summary of 
Changes document dated 29 Aug 
2019 . 
6.0 USA  20Feb2020  2.2.1 Addition of non -clinical data.  
 2.2.2 Addition of clinical data.  
 
3. Update of the outcome measure for 
Duration of Response objective.  
  
3. New exploratory objective investigating relevant tumor 
biomarkers levels.   Additional data available.  
 Additional data available.  
 
To align wording with 
recommendations from competent authorities.   
Increase understanding of the 
relation between biomarker 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 75  
 
 
3. New exploratory objective investigating Recurrence Free Survival 
for patients undergoing metastatic 
resection.  
 
4.1 Clarifying geographical 
stratification.  
 
5.1 Inclusion criteria 4: Addition of lymph nodes.  
 5.5 Update of number of sites and regions  
 6.1.2 and 6.3.1 Defining 5- FU bolus 
duration.  
 
6.2.4 Body Surface Area calculated 
according to DuBois formula.  
 6.2.4.2 Leucovorin administration  
  6.3.3 Allowing use of bevacizumab 
biosimilars.  
 
6.3.4 5- FU dose reduction  
 
6.4.1 Geographical region update  
 
8.1.2 PK sampling timing.   
8.2.2 Clarifying patients position 
during blood pressure and ECG measurements.  
 8.2.5 Clarifying how to manage 
patients becoming eligible for metastasis resection.  
 8.3.4 and 8.4 Update of safety section  
 9.2.4 Overall Survival analysis 
updated.  
 
9.4.9 Addition of recurrence free 
survival.  
 
10.1.5 Update of contact details  
 
10.1.9.2 Additi on of study specific 
Data Entry Instructions and update reg 
eCRF validation.  
 levels and the treatment 
outcome.  
 To compare Recurrence Free Survival data between the treatment groups.  
  Addition on Australia and Japan.  
  Protocol clarification in accordance with RECIST 1.1  
 Protocol clarification.  
 
 
Protocol clarification.  
  
Protocol clarification.  
 
 The supplied Bendafolin contains 
trometamol.  
 
Protocol clarification.  
  Protocol clarification  
 
Protocol clarification  
 
Protocol clarification  
 
Protocol clarification  
 
 
 
Protocol clarification  
  
 
Protocol clarification  
 Clarifying according to FDA 
request.  
 
Protocol clarification  
  Protocol clarification  
 
Protocol clarification  
 
 
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 76 10.1.6 Adding details to the DSMB 
review.  Japan added to the study.  
7.0 USA  20Aug 2021  1.2 Schema Updated  
 
  
2.1.3 Minor clarifications  
 
  
4.4 Follow -up process for patients 
post primary endpoint analysis  
 8.1.2 Update of patients included in 
PK analysis  
 8.1.2.1 Update of analyte in 
population PK analysis and studies 
included in the analysis  
  
 
8.2.2 Patients experiencing a  QTc 
prolongation should be taken of study 
drug  
 
 8.2.4 Section updated and clarified  
  8.2.5 Section updated and clarified  
 
 
8.3.5 Follow -up process for patients 
post primary endpoint analysis  
 9.2.2 Section updated and clarified  
  
9.2.4 Section updated  
   
9.3 Section updated and clarified  
 
 
9.4.6.1 Section updated and clarified  
 
 9.4.6.3 Corrections in Table 5 of errors  
  9.4.6.4 Section updated  
   
 Schema updated as ORR and PFS 
analysis are performed at the same timepoint  
 
Minor clarifications done to improve understanding of mechanism of action  
 
Process clarified as time point for 
ORR and PFS analysis is updated   
Number of patients needed in PK 
evaluation is adjusted  
 Population PK analysis will only 
be done on the active compound 
and not on the metabolites. One previous mentioned study will not be included in the analysi s 
 Previous version stated that patient should be excluded from 
study but patient should only be 
taken off study drug  
 Genes included in the analysis 
are updated 
 Updated as not only metastases are resected during study 
 
Process clarified as time point for ORR and PFS analysis is updated  
 
Correction to ensure wording is not contradicting the SAP  
 
ORR included as the analysis of 
ORR and PFS will be done at the same timepoint  
 
Correction to align wording with 
SAP 
 
Correction to align wording with 
SAP 
 To be aligned with SAP and DSMB 
charter  
 ORR included as the analysis of 
ORR and PFS will be done at the 
same timepoint  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 77 9.4.6.5 Section updated  
 
 
 9.4.7 Section updated and clarified  
 
 
10.1.11 Section clarified related to 
Clinical Study Report  
    
Minor editorial changes  ORR included as the analysis of 
ORR and PFS will be done at the 
same timepoint  
 
To be aligned with SAP and DSMB charter  
 CSR will be writte n when the 
analysis for the primary 
endpoints are available. An 
update of the CSR will done when OS data are available  
 
 
8.0 USA  
(Never submitted, 
changes 
included in version 9.0)  22Feb2022  Number of patients included in the 
study updated in multiple sections  
 
 
Number of PFS events updated in multiple sections  
 
1.1 Synopsis  
 
 
 
2.2.2 Section updated    
 
4.1 and 5.5 Sections updated  
  
 
 9.2.1 Section updated  
    
9.2.2 Section updated  
 
  
 
9.2.4 Section updated  
 
 
   
 
 9.3 Section updated  
   
 Change from 440 patients to 490 
patients as all Japanese patients are included  
 Change from 300 PFS events to 230 PFS events  
 
Study recruitment period 
updated to reflect the actual 
recruitment period  
 Updated with latest safety information from IB V14.0 1Oct2021  
 Information added clarifying that the addition of patients to the ITT population was taken after the 
interim analysis  
 
Addit ion of information on how 
statistical analysis of ORR is 
affected after study population is changed to 490  
Addition of information on how 
statistical analysis of PFS  is 
affected after change in number 
of PFS events  
 Approximate timelines removed. Considerations for OS analysis is 
updated, and wording is deleted 
as PFS hazard ratio has been 
updated but timepoint of OS analysis at 60% remains 
unchanged 
 â€œMain studyâ€ removed as all 490 
patients are included in the 
analys is 
 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 78 9.4.6 Section updated  
 
 
 9.4.7 Section updated  
 
 
 10.1.5 CMO phone number updated 
 
Minor editorial changes  Text updated and added as this 
protocol update is done after the Interim analysis  
 
Information updated in accordance with current version 
of the SAP  
 
Phone number changed 
9.0 USA  22Apr2022  Number of PFS events updated in 
multiple sections  
   9.3 Addition of ITTE analysis set  
 Change from 300 PFS events to at 
least 235 PFS events, to align 
with statistical analysis plan and 
regulatory authority feedback.  
 
Intention -to-Treat Excluding 
Additional Japanese Patients (ITTE) analysis  set added, to be in 
line with current SAP.  
 
  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 79 11 REFERENCES  
[1] Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, 
Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, Fran ce: International Agency for Research on Cancer; 2013. Available from: 
http://globocan.iarc.fr, accessed on 10/May/2014.  
[2] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar -Apr; 61(2):69 -90.  
[3] Longley DB, Harkin DP, Johnston PG. 5 -fluorouracil: mechanisms of action and clinical strategies. 
Nat Rev Cancer. 2003 M ay; 3(5):330 -8. 
[4] E. Van Cutsem, A. Cervantes, R. Adam et al. ESMO Consensus Guidelines for the Management of 
Patients with Metastatic Colorectal Cancer. Annals of Oncology 27: 1386 â€“1422, 2016 
[5] Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with ï¬‚ uorouracil compared with 
ï¬‚uorouracil alone as ï¬ rst-line treatment for metastatic colorectal cancer: a multicentre randomized 
trial. Lancet 2000; 355: 1041â€“ 1047 
[6] de Gramont A, Figer A, Seymour M et al. Leucovorin and ï¬‚ uorouracil with or without oxaliplatin 
as ï¬rst-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938 â€“2947.  
[7] Rustum YM, Trave F, Zakrzewski SF, et al. Biochemical and pharmacologic basis  for potentiation 
of 5-fluorouracil action by leucovorin.  NCI Monogr1987:165 -70 
[8] Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on  the activity and site 
of action of 5 -fluorouracil. Cancer Res1981; 41:3288 -95 
[9] Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5 -ï¬‚uorouracil and 
leucovorin: integrated ef ï¬cacy data and novel analyses from two large, randomized phase III trials. 
Br J Cancer 2004; 90: 1190 â€“1197.  
[10] Cassidy J, Clarke S, DÄ±az -Rubio E et al. Randomized phase III study of capecitabine plus 
oxaliplatin compared with ï¬‚ uorouracil/folinic acid plus oxaliplatin as ï¬rst-line therapy for metastatic 
colorectal cancer. J Clin Oncol 2008; 26: 2006â€“ 2012.  
[11] Tournigand C, AndrÃ© T, Achille E et al. FOLFIRI followed by  FOLFOX6 or the reverse sequence in 
advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229 â€“237.  
[12] Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal 
cancer improves with the availability of ï¬‚ uorouracil leucovorin, irinotecan, and oxaliplatin in the 
course of treatment. J Clin Oncol 2004; 22:1209 â€“1214.  
[13] Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus ï¬‚ uorouracil by 
continuous infusion after ï¬‚uorouracil failure in patients with metastatic colorectal cancer. Lancet 
1998; 352: 1407 â€“1412.  
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 80 [14] Saltz LB, Clarke S, Diaz -Rubio E et al. Bevacizumab in combination with oxaliplatin -based 
chemotherapy as ï¬ rst-line therapy in metastatic colorectal cancer: a randomized phase III study. J 
Clin Oncol 2008; 26: 2013 â€“2019.  
[15] Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, ï¬‚ uorouracil, and 
leucovorin for metastatic colorectal cancer. N Engl J M ed 2004; 350: 2335â€“ 2342.  
[16] Kabbinavar F, Irl C, Zurlo A, Hurwitz H. Bevacizumab improves the overall and progression -free 
survival of patients with metastatic colorectal cancer treated with 5 -ï¬‚uorouracil- based regimens 
irrespective of baseline risk. Onc ology 2008; 75: 215â€“ 223.  
[17] Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine 
alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open -
label, randomized phase 3 trial. Lance t Oncol 2013; 14: 1077â€“ 1085.  
[18] Danenberg P, Gustavsson B, Johnston P, Lindberg P, Moser R, Odin E, Peters GJ & Petrelli N. 
Folates as adjuvants to anticancer agents: chemical rationale and mechanism of action. Crit Rev 
Hematology -Oncology, 2016  Oct;106:118 -31 
[19] Cisneros RJ and Dunlap RB. Characterization of the parameters affecting covalent binding 
stoichiometry in binary and ternary complexes of thymidylate synthase. Biochim Biophys Acta 1990 Jun 19;1039(2):149- 156 
[20] Wettergren Y, Taflin H, Odin E, Kodeda K, and Derwinger K. A pharmacokinetic and 
pharmacodynamic investigation of ModufolinÂ® compared to IsovorinÂ® after single dose intravenous 
administration to patients with colon cancer: a randomized study. Cancer Chemother Pharmacol 2015 Jan;7 5(1):37 -47 
[21] Ford HER, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR, 
Jackman AL.  Patterns of elevation of plasma 2'- deoxyuridine, a surrogate marker of thymidylate 
synthase (TS) inhibition, after administration of two di fferent schedules of 5 -fluorouracil and the 
specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res. 2002 Jan;8(1):103 -9. 
[22] Gustavsson B, Carlsson G, Swartling T, Kurlberg G, Derwinger K, BjÃ¶rkqvist H, Odin E, Gibson F 
Phase 1 dose de-escalation trial of the endogenous folate [6R] -5,10- methylene tetrahydrofolate in 
combination with fixed- dose pemetrexed as neoadjuvant therapy in patients with resectable rectal 
cancer. Invest New Drugs. 2015 Oct;33(5):1078- 85 
[23] Glimelius B, Lahn M.   Window -of-opportunity trials to evaluate clinical activity of new molecular 
entities in oncology.  Ann Oncol.  2011 Aug;22(8):1717 -25. 
[24] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.  New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).  Eur J Cancer.  2009 
Jan;45(2):228- 47. 
[25] Gorin A. MD, Strother D. MD, Poplack D. MD, Letvak L. MD, George M. MD, Link M. MD. Safety 
and Efficacy of l- Leucovorin Rescue Following High -Dose methotrexate for Osteosarcoma. Med 
Pediatric Oncol. 1995 Jun;24(6):362 -7. 
ISO-CC-007 Version 9.0 USA  
ISOFOL Medical AB (publ)  22 April  2022 
 81 [26] Jaffe N, Jorgensen K, Robertson R, George M, Letvak L, Barrett G. Substitution of l- leucovorin for 
d,l-leucovorin in the rescue from high- dose methotrexate treatment in patients with ost eosarcoma. 
Anticancer Drugs. 1993 Oct;4(5):559- 64. 
[27] Hecht J R et al. A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumab 
compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol; 2009; 27(5): 6 72-680 
[28] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. 
Colon Cancer Version 3.2018.  08/07/18  
[29] Van Cutsem  E et al. Safety and efficacy of first -line bevacizumab with FOLFOX, XELOX, FOLFIRI 
and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Annals of Oncology; Volume 20, Issue 11, 1 November 2009: 1842- 1847 
[30] https://ctep.cancer.gov/protoc olDevelopment/electronic_applications/ctc.htm#ctc_50  
[31] United States Food and Drug Administration Guidance for Industry: Clinical Trial Endpoints for 
the Approval of Cancer Drugs and Biologics. Rockville, MD: US Department of Health and Human 
Services; 2007 
[32] Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. 
Biometrics â€”1999 â€”; 55:853 â€“7 
[33] Meta -Analysis Group In Cancer (2004). Modulation of fluorouracil by leucovorin in patients with 
advanced colorectal cancer: an updated meta -analysis. J Clin Oncol 22: 3766 -3775.  
[34] Per-Anders Larsson, GÃ¶ran Carlsson, Bengt Gustavsson, Wilhelm Graf & Bengt Glimelius  (1996)  
Different Intravenous Administration Techniques for 5 -Fluorouracil Pharmacokinetics and 
Pharmacodynamic Effects,  Acta Oncologica,  35:2,  207-212 
 
 
 
  